

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number  
**WO 2004/111220 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 9/58**,  
9/52, 15/57, A23J 3/34

Rahbek; Kvaedevej 111, DK-2830 Virum (DK). **ANDERSEN, Carsten**; Hojeloft Vaenge 162, DK-3500 Værløse (DK). **FISCHER, Morten**; Skovringen 10, DK-2950 Vedbæk (DK).

(21) International Application Number:  
PCT/DK2004/000432

(22) International Filing Date: 21 June 2004 (21.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

PA 2003 00912	19 June 2003 (19.06.2003)	DK
PA 2003 00913	19 June 2003 (19.06.2003)	DK
PA 2003 01494	10 October 2003 (10.10.2003)	DK
PA 2003 01492	10 October 2003 (10.10.2003)	DK
PA 2003 01493	10 October 2003 (10.10.2003)	DK
PA 2004 00331	1 March 2004 (01.03.2004)	DK
PA 2004 00333	1 March 2004 (01.03.2004)	DK
PA 2003 00332	1 March 2004 (01.03.2004)	DK

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **NOVOZYMES A/S** [DK/DK]; Krogshøjvej 36, DK-2880 Bagsvaerd (DK).

**Published:**

— with international search report

(72) Inventors: **LASSEN, Søren**, Flensfød; Gydebakken 3B, DK-3520 Farum (DK). **SJØHOLM, Carsten**; Alleroedvej 17, DK-3450 Alleroed (DK). **ØSTERGAARD, Peter**,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PROTEASES**

(57) Abstract: Thermostable proteases homologous to proteases derived from *Nocardiopsis*, and the production thereof by the wild-type, and in recombinant host cells including transgenic plants and non-human transgenic animals. The proteases are effective in animal feed, in particular fish feed, and detergents. The proteases are capable of degrading the soybean Bowman-Birk inhibitor, and other antinutritional factors such as soybean agglutinin and the Kunitz trypsin inhibitor, as well as the isolated soy storage proteins glycinin and beta-conglycinin. Characteristic structural features of relevance for the thermostability of these proteases of peptidase family S2A or S1E are disclosed.



**WO 2004/111220 A1**

## FIELD OF THE INVENTION

The present invention relates to an isolated polypeptide having protease activity and  
5 being homologous to *Nocardiopsis* proteases, as well as isolated nucleic acid sequences  
encoding it. The invention furthermore relates to nucleic acid constructs, vectors, and host  
cells, including transgenic plants and non-human animals, comprising these nucleic acid  
sequences, as well as methods for producing and using the protease, in particular within  
animal feed, for example in fish feed.

10 The protease of the invention is thermostable, and characteristic structural features of  
relevance for the thermostability of proteases of peptidase family S2A or S1E are disclosed.

The protease of the invention furthermore effectively degrades the soybean Bowman-  
Birk inhibitor, as well as other anti-nutritional factors such as soybean agglutinin, and the  
Kunitz trypsin inhibitor, and also isolated soy storage proteins such as, glycinin and beta-  
15 conglycinin.

## BACKGROUND OF THE INVENTION

Proteases derived from *Nocardiopsis* sp. NRRL 18262 and *Nocardiopsis dassonvillei*  
NRRL 18133 are disclosed in WO 88/03947. The DNA and amino acid sequences of the  
20 protease derived from *Nocardiopsis* sp. NRRL 18262 are shown in DK application no. 1996  
00013. WO 01/58276 discloses the use in animal feed of acid-stable proteases related to the  
protease derived from *Nocardiopsis* sp. NRRL 18262, as well as a protease derived from  
*Nocardiopsis alba* DSM 14010. These proteases, however, are not thermostable.

JP 2-255081-A discloses a protease derived from *Nocardiopsis* sp. strain OPC-210  
25 (FERM P-10508), however without sequence information. The strain is no longer available,  
as the deposit was withdrawn.

DD 200432[8] discloses a proteolytic preparation derived from *Nocardiopsis*  
*dassonvillei* strain ZIMET 43647, however without sequence information. The strain appears  
to be no longer available.

30 JP 2003284571-A, published after the first filing date of the present invention,  
discloses the amino acid sequence and the corresponding DNA sequence of a protease  
derived from *Nocardiopsis* sp. TOA-1 (FERM P-18676). The sequence has been entered in  
GENESEQP with no. ADF43564.

Thermostable proteases are described in the prior art, for example a protease from  
35 *Thermomonospora fusca* YX is described by Lao and Wilson in Appl. Environ. Microbiol.  
62:4256-4259 (1996), and the sequence was filed in the public databases as

spirembi\_086984. However, this protease is not homologous to *Nocardiosis* proteases, as the percentage identity to the proteases of the invention is below 60%.

It is an object of the present invention to provide thermostable proteases that are homologous to *Nocardiosis* proteases, in particular with a potential for use in animal feed and/or detergents.

## SUMMARY OF THE INVENTION

A number of thermostable proteases were isolated and characterized, viz. a protease derived from *Nocardiosis dassonvillei* subsp. *dassonvillei* DSM 43235 (see SEQ ID NOs: 1 and 2); a synthetic Protease 22 (see SEQ ID NOs: 7 and 8); a protease L2a derived from *Nocardiosis* sp. DSM 16424 (see SEQ ID NOs: 9 and 10); and Protease 8 derived from *Nocardiosis alba* DSM 15647 (see SEQ ID NOs: 11 and 12).

In a first aspect, the invention relates to an isolated polypeptide having protease activity, and having a melting temperature ( $T_m$ ) of at least 78°C, as determined by Differential Scanning Calorimetry (DSC) in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0, using a constant scan rate of 1.5°C/min, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12 of at least 60%; (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under low stringency conditions with either of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11; and (c) a polypeptide which is encoded by a nucleic acid sequence which has a degree of identity to any one of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%. The invention also relates to isolated nucleic acid sequences encoding such proteases; nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences; as well as methods for producing and using the proteases, in particular within animal feed.

In a second aspect, the invention relates to:

A. An isolated polypeptide of peptidase family S2A and/or peptidase family S1E having protease activity, and having an amino sequence comprising at least one of the following amino acids at the position indicated: 10Y, 24S, 38T, 42G, 49T, 51T, 53Q, 54N, 82S, 86Q, 87S, 89T, 91T, 92S, 96A, 99A, 118N, 120T, 122R, 125Q, 129Y, 130S, 131L, 135N, 147F, 151S, 165S, 166V, 171Y, 179I, and/or 186I; preferably 10Y, 38T, 82S, 99A, 118N, 120T, 122R, 125Q, 129Y, 130S, 131L, 165S, and/or 171Y; more preferably together with at least one of 95P, 100V, and/or 114I; and/or together with (H35 + D61 + S143); wherein each position corresponds to a position of SEQ ID NO: 2;

- B. The polypeptide of B which comprises at least one of the following amino acids at the position indicated: 38T, 92S, 120T, 125Q, 131L, 135N, 147F, 151S, 165S, and/or 171Y;
- C. The polypeptide of A which comprises at least one of the following amino acids at the position indicated: 10Y, 24S, 42G, 49T, 51T, 53Q, 54N, 82S, 86Q, 87S, 89T, 91T, 96A, 99A, 118N, 122R, 129Y, 130S, 166V, 179I, and/or 186I;
- 5 D. An isolated polypeptide of peptidase family S2A and/or peptidase family S1E having protease activity, and having an amino sequence comprising at least one of the following amino acids at the position indicated: 25S, 38T, 42P, 44S, 49Q, 54R, 62S, 89S, 91S, 92S, 95A, 99Q, 100I, 114V, 120T, 125Q, 129Q, 131L, 135N, 147F, 151S, 165S, 166F, 171Y, 10 176N, 179L, 180S, 184L, and/or 185T; preferably 25S, 38T, 42P, 44S, 54R, 62S, 125Q, 131L, 165S, 171Y, 176N, 179L, 180S, 184L, and/or 185T; more preferably together with at least one of 24A, 51V, 53E, 86A, 87T, 96I, and/or 186L; and/or together with (H35 + D61 + S143); wherein each position corresponds to a position of SEQ ID NO: 12.
- E. The polypeptide of D which comprises at least one of the following amino acids at the position indicated: 38T, 92S, 120T, 125Q, 131L, 135N, 147F, 151S, 165S, and/or 171Y.
- 15 F. The polypeptide of D which comprises at least one of the following amino acids at the position indicated: 25S, 42P, 44S, 49Q, 54R, 62S, 89S, 91S, 95A, 99Q, 100I, 114V, 129Q, 166F, 176N, 179L, 180S, 184L, and/or 185T.
- G. The polypeptide of any one of A, B, C, D, E, and F which has a  $T_m$  of at least 78°C as measured by DSC in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0; and/or a relative activity at pH9 and 80°C of at least 0.40;
- 20 H. The polypeptide of any one of A, B, C, D, E, F, and G which has a percentage of identity of at least 60% to either of amino acids -166 to 188, preferably 1-188, of SEQ ID NO: 2; amino acids -192 to 196, preferably 1-196, of SEQ ID NO: 8; amino acids -195 to 189, preferably 1-189 of SEQ ID NO: 10; and/or to amino acids -167 to -1, preferably 1-188, of SEQ ID NO: 12;
- 25 I. The polypeptide of any one of A, B, C, D, E, F, G; and H which is i) a bacterial protease; ii) a protease of the phylum *Actinobacteria*; iii) of the class *Actinobacteria*; iv) of the order *Actinomycetales* v) of the family *Nocardiopsaceae*; vi) of the genus *Nocardiopsis*; and/or a protease derived from vii) *Nocardiopsis* species such as *Nocardiopsis alba*, *Nocardiopsis alkaliphila*, *Nocardiopsis antarctica*, *Nocardiopsis prasina*, *Nocardiopsis composita*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, *Nocardiopsis xinjiangensis*, or *Nocardiopsis dassonvillei*, e.g. a protease derived from *Nocardiopsis antarctica* or *Nocardiopsis dassonvillei*, for example *Nocardiopsis dassonvillei* DSM 43235, *Nocardiopsis* sp. DSM 16424, or *Nocardiopsis alba*
- 30
- 35

DSM 15647, such as a polypeptide with the amino acid sequence of the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, or 12;

- J. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of any one of A, B, C, D, E, F, G, H or I;
- 5 K. A nucleic acid construct comprising the nucleic acid sequence of J operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host;
- L. A recombinant expression vector comprising the nucleic acid construct of K;
- M. A recombinant host cell comprising the nucleic acid construct of K or the vector of L;
- 10 N. A method for producing a polypeptide of any one of A, B, C, D, E, F, G, H, or I, the method comprising: (a) cultivating a recombinant host cell of M to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide;
- O. A transgenic plant, or plant part, capable of expressing the polypeptide of any one of A, B, C, D, E, F, G, H, or I;
- 15 P. A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the polypeptide of any one of A, B, C, D, E, F, G, H, or I;
- Q. Use of at least one polypeptide as defined in A, B, C, D, E, F, G, H, or I (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of an animal feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins;
- 20 R. An animal feed additive comprising at least one polypeptide as defined in any one of A, B, C, D, E, F, G, H or I; and (a) at least one fat-soluble vitamin, and/or (b) at least one water-soluble vitamin, and/or (c) at least one trace mineral;
- 25 S. An animal feed composition, preferably a fish feed, having a crude protein content of 50 to 800 g/kg and comprising at least one polypeptide as defined in any one of A, B, C, D, E, F, G, H, or I; or at least one feed additive of R;
- T. A composition comprising at least one polypeptide as defined in any one of claims A, B, C, D, E, F, G, H, or I, together with at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6); as well as
- 30 U. Use of at least one polypeptide as defined in any one of A, B, C, D, E, F, G, H or I in detergents.

In a third aspect, the invention relates to:

- I. An isolated polypeptide having protease activity, which after incubation for four hours at 37°C and pH 6.5 has degraded at least 36% (preferably at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or at least 81%) of the soybean Bowman-Birk inhibitor, said percentage degradation being determined as 100% minus the percentage intensity of the intact Bowman-Birk inhibitor band on a stained SDS-PAGE (Tris-Glycine 4-20%) gel after the incubation, relative to the intensity of the same band before the incubation, said intensities of said bands being determined by scanning the gel; wherein the polypeptide is selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12 of at least 60%; (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under low stringency conditions with either of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11; and (c) a polypeptide which is encoded by a nucleic acid sequence which has a degree of identity to any one of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%;
- II. The polypeptide of I, wherein the incubation takes place in an incubation buffer containing 50 mM dimethyl glutaric acid, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.01% Triton X-100, pH 6.5;
- III. The polypeptide of any one of I, or II, wherein, during the incubation, the ratio between the protease polypeptide and the Bowman-Birk inhibitor is 1:10, based on A<sub>280</sub>;
- IV. The polypeptide of any one of I, II, or III, wherein the gel is stained with Coomassie Brilliant Blue;
- V. The polypeptide of any one of I, II, III, or IV, wherein the Bowman-Birk inhibitor is Sigma T-9777;
- VI. The polypeptide of any one of I, II, III, IV, or V, being further capable of degrading at least one of the following purified soy proteins: Soybean agglutinin (SBA), the Kunitz trypsin inhibitor, glycinin, and/or beta-conglycinin, using the principles as described in any one of I, II, III, IV, or V;
- VII. The polypeptide of claim VI which has degraded at least one of the purified soy proteins to an extent of at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 92%, 94%, 96%, or at least 98%;
- VIII. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of any one of I, II, III, IV, V, VI, or VII;
- IX. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes a polypeptide having protease activity, which polypeptide, after incubation for four hours at 37°C and pH 6.5, has degraded at least 36% (preferably at least 40%, 45%, 50%,

55%, 60%, 65%, 70%, 75%, 80%, or at least 81%) of the soybean Bowman-Birk inhibitor, said percentage degradation being determined as 100% minus the percentage intensity of the intact Bowman-Birk inhibitor band on a stained SDS-PAGE (Tris-Glycine 4-20%) gel after the incubation, relative to the intensity of the same band before the incubation, said intensities of said bands being determined by scanning the gel; wherein the nucleic acid sequence (a) hybridizes under low stringency conditions with either of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11; (b) has a degree of identity to any one of nucleotides 499-1062 of SEQ ID NO: 1577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%; and/or (c) encodes a polypeptide which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12 of at least 60%;

X. A nucleic acid construct comprising the nucleic acid sequence of any one of VIII, or IX, operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host;

XI. A recombinant expression vector comprising the nucleic acid construct of X;

XII. A recombinant host cell comprising the nucleic acid construct of X or the vector of XI;

XIII. A method for producing a polypeptide of I, the method comprising: (a) cultivating a recombinant host cell of XII to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide;

XIII. A transgenic plant, or plant part, capable of expressing the polypeptide of I;

XIV. A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the polypeptide of I;

XV. A method for producing a polypeptide of I, the method comprising (a) cultivating any one of the following strains: (i) *Nocardioopsis dassonvillei* subsp. *dassonvillei* DSM 43235, (ii) *Nocardioopsis* sp. DSM 16424, or (iii) *Nocardioopsis alba* DSM 15647; and (b) recovering the polypeptide;

XVI. Use of at least one polypeptide as defined in I (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of an animal feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins;

XVII. An animal feed additive comprising at least one polypeptide as defined in I; and (a) at least one fat-soluble vitamin, and/or (b) at least one water-soluble vitamin, and/or (c) at least one trace mineral;

IXX. An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one polypeptide as defined in I, or at least one feed additive of XVII;

IXX. The feed composition of IXX which is a fish feed;



XX. A composition comprising at least one polypeptide as defined in I, together with at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6); as well as

XXI. Use of at least one polypeptide as defined in I in detergents.

In a fourth aspect, the invention relates to:

a. An isolated polypeptide having protease activity, selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has a degree of identity (i) to amino acids 1 to 188 of SEQ ID NO: 2 of at least 85%, (ii) to amino acids 1 to 196 of SEQ ID NO: 8 of at least 85%, (iii) to amino acids 1-189 of SEQ ID NO: 10 of at least 85%, and/or a degree of identity to amino acids 1-188 of SEQ ID NO: 12 of at least 89%; (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under medium-high stringency conditions with (i) nucleotides 499-1062 of SEQ ID NO: 1, (ii) nucleotides 577-1164 of SEQ ID NO: 7, (iii) nucleotides 586-1152 of SEQ ID NO: 9, (iv) nucleotides 502-1065 of SEQ ID NO: 11, (v) a subsequence of any one of (i)-(iv) of at least 100 nucleotides; and/or (vi) a complementary strand of any one of (i)-(v); (c) a variant of the polypeptide having an amino acid sequence of (i) amino acids 1 to 188 of SEQ ID NO: 2, (ii) amino acids 1 to 196 of SEQ ID NO: 8, (iii) amino acids 1-189 of SEQ ID NO: 10, or amino acids 1-188 of SEQ ID NO: 12, comprising a substitution, deletion, extension, and/or insertion of one or more amino acids; (d) an allelic variant of (a), (b), or (c); and (e) a fragment of (a), (b), (c), or (d) that has protease activity;

b. An isolated nucleic acid sequence comprising a nucleic acid sequence which (a) encodes the polypeptide of a; (b) encodes a polypeptide having protease activity, and which hybridizes under medium-high stringency conditions with (i) nucleotides 499-1062 of SEQ ID NO: 1, (ii) nucleotides 577-1164 of SEQ ID NO: 7, (iii) nucleotides 586-1152 of SEQ ID NO: 9, (iv) nucleotides 502-1065 of SEQ ID NO: 11, (v) a subsequence of any one of (i)-(iv) of at least 100 nucleotides; and/or (vi) a complementary strand of any one of (i)-(v); and/or (c) encodes a polypeptide having protease activity and which has a degree of identity (i) to nucleotides 499-1062 of SEQ ID NO: 1 of at least 86%, (ii) to nucleotides 577-1164 of SEQ ID NO: 7 of at least 65%, (iii) to nucleotides 586-1152 of SEQ ID NO: 9 of at least 85%, (iv) to nucleotides 502-1065 of SEQ ID NO: 11 of at least 89%;

c. An isolated nucleic acid sequence produced by (a) hybridizing a DNA under medium-high stringency conditions with (i) nucleotides 499-1062 of SEQ ID NO: 1, (ii) nucleotides 577-1164 of SEQ ID NO: 7, (iii) nucleotides 586-1152 of SEQ ID NO: 9, (iv) nucleotides 502-1065 of SEQ ID NO: 11, (v) a subsequence of any one of (i)-(iv) of at least 100 nucleotides;



and/or (vi) a complementary strand of any one of (i)-(v); and (b) isolating the nucleic acid sequence;

- 5 *d.* A nucleic acid construct comprising the nucleic acid sequence of any one of *b*, or *c*, operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host;
- e.* A recombinant expression vector comprising the nucleic acid construct of *d*;
- f.* A recombinant host cell comprising the nucleic acid construct of *d* or the vector of *e*;
- g.* A method for producing a polypeptide of *a*, the method comprising: (a) cultivating a recombinant host cell of *f* to produce a supernatant comprising the polypeptide; and (b)
- 10 recovering the polypeptide;
- h.* A transgenic plant, or plant part, capable of expressing the polypeptide of *a*;
- i.* A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the polypeptide of *a*;
- j.* A method for producing a polypeptide of *a*, the method comprising (a) cultivating any
- 15 one of the following strains: (i) *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235, (ii) *Nocardiopsis* sp. DSM 16424, or *Nocardiopsis alba* DSM 15647; and (b) recovering the polypeptide;
- k.* Use of at least one polypeptide as defined in *a* (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of an animal
- 20 feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins;
- l.* An animal feed additive comprising at least one polypeptide as defined in *a*; and (a) at least one fat-soluble vitamin, and/or (b) at least one water-soluble vitamin, and/or (c) at least one trace mineral;
- 25 *m.* An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one polypeptide as defined in *a*, or at least one feed additive of *l*;
- n.* The feed composition of *m* which is a fish feed;
- o.* A composition comprising at least one polypeptide as defined in *a*, together with at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC
- 30 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6); as well as
- p.* Use of at least one polypeptide as defined in *a* in detergents.
- 35 In a fifth aspect, the invention relates to: an isolated polypeptide having protease activity, selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 188

of SEQ ID NO: 8, 1 to 196 of SEQ ID NO: 8, and/or to of at least 84%; (b) a polypeptide having an amino acid sequence which has a degree of identity to amino acids -166 to 188 of SEQ ID NO: 2, and/or -192 to 196 of SEQ ID NO: 8, of at least 75%; (c) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under medium-high stringency conditions with (i) DNA encoding a protease obtainable from genomic DNA from *Nocardioopsis dassonvillei* subspecies *dassonvillei* DSM 43235 by use of primers SEQ ID NOs: 3 and 4; (ii) nucleotides 499-1062 of SEQ ID NO: 1, and/or 577-1164 of SEQ ID NO: 7; (iii) nucleotides 1-1062 of SEQ ID NO: 1, and/or 1-1164 of SEQ ID NO: 7; (iv) a subsequence of (i) or (ii) or (iii) of at least 100 nucleotides; and/or (v) a complementary strand of (i), (ii), (iii) or (iv); (d) a variant of the polypeptide having an amino acid sequence of amino acids 1 to 188, or -166 to 188 of SEQ ID NO: 2, or amino acids 1 to 196, or -192 to 196 of SEQ ID NO: 8, comprising a substitution, deletion, extension, and/or insertion of one or more amino acids; (e) an allelic variant of (a), (b) or (c); and (f) a fragment of (a), (b), (c), (d) or (e) that has protease activity;

An isolated polypeptide having protease activity, and having a melting temperature ( $T_m$ ) of at least 78°C, as determined by Differential Scanning Calorimetry (DSC) in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0, using a constant scan rate of 1.5 °C/min, wherein the polypeptide is selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 188 of SEQ ID NO: 8, and/or 1 to 196 of SEQ ID NO: 8, of at least 50%; (b) a polypeptide having an amino acid sequence which has a degree of identity to amino acids -166 to 188 of SEQ ID NO: 2, and/or -192 to 196 of SEQ ID NO: 8, of at least 50%; (c) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under low stringency conditions with DNA encoding a protease obtainable from genomic DNA from *Nocardioopsis dassonvillei* subspecies *dassonvillei* DSM 43235 by use of primers SEQ ID NOS. 3 and 4; nucleotides 499-1062 of SEQ ID NO: 1, and/or 577-1164 of SEQ ID NO: 7; nucleotides 1-1062 of SEQ ID NO: 1, and/or 1-1164 of SEQ ID NO: 7; a subsequence of (i) or (ii) or (iii) of at least 100 nucleotides; and/or a complementary strand of (i), (ii), (iii) or (iv); (d) a variant of the polypeptide having an amino acid sequence of amino acids 1 to 188, or -166 to 188 of SEQ ID NO: 2, or amino acids 1 to 196, or -192 to 196 of SEQ ID NO: 8, comprising a substitution, deletion, extension, and/or insertion of one or more amino acids; (e) an allelic variant of (a), (b) or (c); and (f) a fragment of (a), (b), (c), (d) or (e) that has protease activity;

An isolated nucleic acid sequence comprising a nucleic acid sequence which (a) encodes the polypeptide of claim 1; (b) encodes a polypeptide having protease activity, and which hybridizes under medium-high stringency conditions with (i) DNA encoding a protease obtainable from genomic DNA from *Nocardioopsis dassonvillei* subspecies *dassonvillei* DSM

43235 by use of primers SEQ ID NOS. 3 and 4; (ii) nucleotides 499-1062 or 1-1062 of SEQ ID NO: 1, and/or 577-1164 or 1-1164 of SEQ ID NO: 7; (iii) a subsequence of (i) or (ii) of at least 100 nucleotides; and/or (iv) a complementary strand of (i), (ii), or (iii); (c) encodes a polypeptide having protease activity and which has a degree of identity to nucleotides 499-1062 SEQ ID NO: 1, and/or 577-1164 of SEQ ID NO: 7, of at least 85%; and/or (d) encodes a polypeptide having protease activity and which has a degree of identity to nucleotides 1-1062 SEQ ID NO: 1, and/or nucleotides 1-1164 of SEQ ID NO: 7, of at least 81%;

An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes a polypeptide having protease activity and a melting temperature ( $T_m$ ) of at least 78°C, as determined by Differential Scanning Calorimetry (DSC) in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0, using a constant scan rate of 1.5 °C/min, wherein the nucleic acid sequence (a) encodes the above polypeptide; (b) hybridizes under low stringency conditions with DNA encoding a protease obtainable from genomic DNA from *Nocardiopsis dassonvillei subspecies dassonvillei* DSM 43235 by use of primers SEQ ID NO's: 3 and 4; nucleotides 499-1062 or 1-1062 of SEQ ID NO: 1, and/or 577-1164 or 1-1164 of SEQ ID NO: 7; a subsequence of (i) or (ii) of at least 100 nucleotides; and/or a complementary strand of (i), (ii), or (iii); (c) has a degree of identity to nucleotides 499-1062 of SEQ ID NO: 1, and/or 577-1164 of SEQ ID NO: 7, of at least 50%; and/or (d) has a degree of identity to nucleotides 1-1062 of SEQ ID NO: 1, and/or 1-1164 of SEQ ID NO: 7, of at least 50%;

An isolated nucleic acid sequence produced by (a) hybridizing a DNA under medium-high stringency conditions with DNA encoding a protease obtainable from genomic DNA from *Nocardiopsis dassonvillei subspecies dassonvillei* DSM 43235 by use of primers SEQ ID NOS. 3 and 4; nucleotides 499-1062 or 1-1062 of SEQ ID NO: 1, and/or 577-1164 or 1-1164 of SEQ ID NO: 7; a subsequence of (i) or (ii) of at least 100 nucleotides; or a complementary strand of (i), (ii) or (iii); and (b) isolating the nucleic acid sequence;

A nucleic acid construct comprising the above nucleic acid sequence operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host;

A recombinant expression vector comprising the nucleic acid construct;

A recombinant host cell comprising the nucleic acid construct or the vector;

A method for producing the above polypeptide, the method comprising: (a) cultivating a recombinant host cell of claim 8 to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide;

A transgenic plant, or plant part, capable of expressing the above polypeptide;

A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the above polypeptide;

Use of at least one of the above polypeptides (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of an animal feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins;

5 An animal feed additive comprising at least one polypeptide as defined above; and (a) at least one fat-soluble vitamin, and/or (b) at least one water-soluble vitamin, and/or (c) at least one trace mineral;

An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one polypeptide as defined above, or at least one feed additive;

10 A composition comprising at least one polypeptide as defined above, together with at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 15 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6);

Use of at least one polypeptide as defined above in detergents;

An isolated polypeptide of peptidase family S2A and/or peptidase family S1E having protease activity, and having an amino sequence comprising at least one of the following amino acids at the position indicated: 10Y, 24S, 38T, 42G, 49T, 51T, 53Q, 54N, 82S, 86Q, 20 87S, 89T, 91T, 92S, 96A, 99A, 118N, 120T, 122R, 125Q, 129Y, 130S, 131L, 135N, 147F, 151S, 165S, 166V, 171Y, 179I, and/or 186I; preferably 10Y, 38T, 82S, 95P, 99A, 100V, 114I, 118N, 120T, 122R, 125Q, 129Y, 130S, 131L, 165S, and/or 171Y; more preferably together with at least one of 95P, 100V, and/or 114I; and/or together with (H35 + D61 + S143); wherein each position corresponds to a position of SEQ ID NO: 2;

25 The above family S2A or S1E polypeptide which comprises at least one of the following amino acids at the position indicated: 38T, 92S, 120T, 125Q, 131L, 135N, 147F, 151S, 165S, and/or 171Y;

The above family S2A or S1E polypeptide which comprises at least one of the following amino acids at the position indicated: 10Y, 24S, 42G, 49T, 51T, 53Q, 54N, 82S, 30 86Q, 87S, 89T, 91T, 96A, 99A, 118N, 122R, 129Y, 130S, 166V, 179I, and/or 186I;

The above family S2A or S1E polypeptide which has a T<sub>m</sub> of at least 78°C as measured by DSC in 10mM sodium phosphate, 50 mM sodium chloride, pH 7.0; and/or a relative activity at pH9 and 80°C of at least 0.40;

35 The above family S2A or S1E polypeptide which has a percentage of identity to amino acids 1-188, or -166 to 188, of SEQ ID NO: 2, and/or to amino acids 1-196, or -192 to 196, of SEQ ID NO: 8, of at least 50%;

The above family S2A or S1E polypeptide which is i) a bacterial protease; ii) a protease of the phylum *Actinobacteria*; iii) of the class *Actinobacteria*; iv) of the order *Actinomycetales* v) of the family *Nocardiopsaceae*; vi) of the genus *Nocardiopsis*; and/or a protease derived from vii) *Nocardiopsis* species such as *Nocardiopsis alba*, *Nocardiopsis antarctica*, *Nocardiopsis prasina*, *Nocardiopsis composta*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, *Nocardiopsis xinjiangensis*, or *Nocardiopsis dassonvillei*, e.g. a protease derived from *Nocardiopsis antarctica* or *Nocardiopsis dassonvillei*, for example *Nocardiopsis dassonvillei* DSM 43235, such as a polypeptide with the amino acid sequence of amino acids 1 to 188, or -166 to 188, of SEQ ID NO: 2;

An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the above family S2A or S1E polypeptide;

A nucleic acid construct comprising the nucleic acid sequence operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host;

A recombinant expression vector comprising the nucleic acid construct;

A recombinant host cell comprising the nucleic acid construct or the vector;

A method for producing the above family S2A or S1E polypeptide, the method comprising: (a) cultivating a recombinant host cell to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide;

A transgenic plant, or plant part, capable of expressing the above family S2A or S1E polypeptide;

A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the above family S2A or S1E polypeptide;

Use of at least one of the above S2A or S1E polypeptides (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of an animal feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins;

An animal feed additive comprising at least one one of the above S2A or S1E polypeptides; and (a) at least one fat-soluble vitamin, and/or (b) at least one water-soluble vitamin, and/or (c) at least one trace mineral;

An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one one of the above S2A or S1E polypeptides, or at least one above feed additive;

A composition comprising at least one one of the above S2A or S1E polypeptides, together with at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32);  
5 phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6); as well as

Use of at least one one of the above S2A or S1E polypeptides in detergents.

The above second, third, fourth, and fifth aspects, are, independently of each other, also preferred sub-aspects of the first aspect of the invention, as well as preferred sub-  
10 aspects of each other.

## DETAILED DESCRIPTION OF THE INVENTION

Polypeptides having protease activity, or proteases, are sometimes also designated peptidases, proteinases, peptide hydrolases, or proteolytic enzymes. Proteases may be of  
15 the exo-type that hydrolyses peptides starting at either end thereof, or of the endo-type that act internally in polypeptide chains (endopeptidases). Endopeptidases show activity on N- and C-terminally blocked peptide substrates that are relevant for the specificity of the protease in question.

The term "protease" is defined herein as an enzyme that hydrolyses peptide bonds. It  
20 includes any enzyme belonging to the EC 3.4 enzyme group (including each of the thirteen subclasses thereof). The EC number refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including supplements 1-5 published in Eur. J. Biochem. 1994, 223, 1-5; Eur. J. Biochem. 1995, 232, 1-6; Eur. J. Biochem. 1996, 237, 1-5; Eur. J. Biochem. 1997, 250, 1-6; and Eur. J. Biochem. 1999, 264, 610-650; respectively. The  
25 nomenclature is regularly supplemented and updated; see e.g. the World Wide Web (WWW) at <http://www.chem.qmw.ac.uk/iubmb/enzyme/index.html>.

Proteases are classified on the basis of their catalytic mechanism into the following groups: Serine proteases (S), Cysteine proteases (C), Aspartic proteases (A), Metallo proteases (M), and Unknown, or as yet unclassified, proteases (U), see Handbook of  
30 Proteolytic Enzymes, A.J.Barrett, N.D.Rawlings, J.F.Woessner (eds), Academic Press (1998), in particular the general introduction part.

In particular embodiments, the proteases of the invention and for use according to the invention are selected from the group consisting of:

- (a) Proteases belonging to the EC 3.4.-.- enzyme group;
- 35 (b) Serine proteases belonging to the S group of the above Handbook;
- (c) Serine proteases of peptidase family S2A; and/or

(d) Serine proteases of peptidase family S1E as described in Biochem.J. 290:205-218 (1993) and in MEROPS protease database, release 6.20, March 24, 2003, (www.merops.ac.uk). The database is described in Rawlings, N.D., O'Brien, E. A. & Barrett, A.J. (2002) *MEROPS: the protease database*. Nucleic Acids Res. 30, 343-346.

5 For determining whether a given protease is a Serine protease, and a family S2A protease, reference is made to the above Handbook and the principles indicated therein. Such determination can be carried out for all types of proteases, be it naturally occurring or wild-type proteases; or genetically engineered or synthetic proteases.

Protease activity can be measured using any assay, in which a substrate is  
10 employed, that includes peptide bonds relevant for the specificity of the protease in question. Assay-pH and assay-temperature are likewise to be adapted to the protease in question. Examples of assay-pH-values are pH 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12. Examples of assay-temperatures are 30, 35, 37, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 95°C.

Examples of protease substrates are casein, such as Azurine-Crosslinked Casein  
15 (AZCL-casein). Two protease assays are described in Example 2 herein, either of which can be used to determine protease activity. For the purposes of this invention, the so-called pNA Assay is a preferred assay.

There are no limitations on the origin of the protease of the invention and/or for use according to the invention. Thus, the term protease includes not only natural or wild-type  
20 proteases obtained from microorganisms of any genus, but also any mutants, variants, fragments etc. thereof exhibiting protease activity, as well as synthetic proteases, such as shuffled proteases, and consensus proteases. Such genetically engineered proteases can be prepared as is generally known in the art, e.g. by Site-directed Mutagenesis, by PCR (using a PCR fragment containing the desired mutation as one of the primers in the PCR reactions),  
25 or by Random Mutagenesis. The preparation of consensus proteins is described in e.g. EP 897985. Gene shuffling is generally described in e.g. WO 95/22625 and WO 96/00343. Recombination of protease genes can be made independently of the specific sequence of the parents by synthetic shuffling as described in Ness, J.E. et al, in Nature Biotechnology, Vol. 20 (12), pp. 1251-1255, 2002. Synthetic oligonucleotides degenerated in their DNA  
30 sequence to provide the possibility of all amino acids found in the set of parent proteases are designed and the genes assembled according to the reference. The shuffling can be carried out for the full length sequence or for only part of the sequence and then later combined with the rest of the gene to give a full length sequence. The proteases of the mature peptide parts of SEQ ID NOs: 2, 8, 10 and 12, such as Protease 22 (SEQ ID NO: 8), and the protease  
35 derived from *Nocardioptosis dassonvillei subspecies dassonvillei* DSM 43235 (SEQ ID NO: 2), are particular examples of such parent proteases which can be subjected to shuffling as described above, if desired together with the protease derived from *Nocardioptosis sp.* NRRL



18262, to provide additional proteases of the invention. The term "obtained from" as used herein in connection with a given source shall mean that the polypeptide encoded by the nucleic acid sequence is produced by the source or by a cell in which the nucleic acid sequence from the source is present. In a preferred embodiment, the polypeptide is secreted  
5 extracellularly.

In a specific embodiment, the protease is a low-allergenic variant, designed to invoke a reduced immunological response when exposed to animals, including man. The term immunological response is to be understood as any reaction by the immune system of an animal exposed to the protease. One type of immunological response is an allergic response  
10 leading to increased levels of IgE in the exposed animal. Low-allergenic variants may be prepared using techniques known in the art. For example the protease may be conjugated with polymer moieties shielding portions or epitopes of the protease involved in an immunological response. Conjugation with polymers may involve *in vitro* chemical coupling of polymer to the protease, e.g. as described in WO 96/17929, WO 98/30682, WO 98/35026,  
15 and/or WO 99/00489. Conjugation may in addition or alternatively thereto involve *in vivo* coupling of polymers to the protease. Such conjugation may be achieved by genetic engineering of the nucleotide sequence encoding the protease, inserting consensus sequences encoding additional glycosylation sites in the protease and expressing the protease in a host capable of glycosylating the protease, see e.g. WO 00/26354. Another  
20 way of providing low-allergenic variants is genetic engineering of the nucleotide sequence encoding the protease so as to cause the protease to self-oligomerize, effecting that protease monomers may shield the epitopes of other protease monomers and thereby lowering the antigenicity of the oligomers. Such products and their preparation is described e.g. in WO 96/16177. Epitopes involved in an immunological response may be identified by  
25 various methods such as the phage display method described in WO 00/26230 and WO 01/83559, or the random approach described in EP 561907. Once an epitope has been identified, its amino acid sequence may be altered to produce altered immunological properties of the protease by known gene manipulation techniques such as site directed mutagenesis (see e.g. WO 00/26230, WO 00/26354 and/or WO 00/22103) and/or  
30 conjugation of a polymer may be done in sufficient proximity to the epitope for the polymer to shield the epitope.

A polypeptide according to either aspect of the present invention may comprise an amino acid sequence which has a degree of identity to the mature peptide part of either of SEQ ID NOs: 2, 8, 10, or 12, for example amino acids 1 to 188 of SEQ ID NO: 2, and/or to  
35 amino acids 1 to 196 of SEQ ID NO: 8 (the mature peptide parts), of, for example, at least about 60%, and which have protease activity (hereinafter "homologous polypeptides"). In particular embodiments, the degree of identity to either of the mature peptide parts of either

of SEQ ID NOs: 2, 8, 10 or 12 is at least about 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99%. In alternative embodiments, the degree of identity is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, or at least about 59%.

5 In particular embodiments, the polypeptides of the invention i) have; or ii) consist of an amino acid sequence with any of the degrees of identity as mentioned above.

For the purposes of the present invention, the degree of identity between two amino acid sequences, as well as the degree of identity between two nucleotide sequences, is determined by the program "align" which is a Needleman-Wunsch alignment (i.e. a global  
10 alignment). The program is used for alignment of polypeptide, as well as nucleotide sequences. The default scoring matrix BLOSUM50 is used for polypeptide alignments, and the default identity matrix is used for nucleotide alignments. The penalty for the first residue of a gap is -12 for polypeptides and -16 for nucleotides. The penalties for further residues of a gap are -2 for polypeptides, and -4 for nucleotide.

15 "Align" is part of the FASTA package version v20u6 (see W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," Methods in Enzymology 183:63-98). FASTA protein alignments use the Smith-Waterman algorithm with no limitation on gap size (see "Smith-Waterman algorithm", T. F.  
20 Smith and M. S. Waterman (1981) J. Mol. Biol. 147:195-197).

In a particular embodiment, the mature peptide parts, or predicted or expected mature peptide parts, of the two amino acid sequences are used for the alignment. In the alternative, that part of the sequence, whose identity to the mature peptide part of SEQ ID NO: 2 and/or SEQ ID NO: 8 is being examined, is chosen, which according to a multiple  
25 alignment made as described below is most similar to the mature peptide part of SEQ ID NO: 2 and/or 8, i.e. the corresponding amino acid residues as identified by the multiple alignment.

In the present context, the basis for numbering amino acid residues or assigning position numbers, cf. the second aspect of the invention, is SEQ ID NO: 2 starting with A1 and ending with T188. In the alternative, the basis is amino acids 1-188 of the protease  
30 derived from *Nocardiosis sp.* NRRL 18262 (SEQ ID NO: 1 as disclosed in WO 01/58276, preferably SEQ ID NO: 1 as disclosed in WO 01/58276 in which A87 is substituted with T87. Proteases may comprise extensions as compared to these reference sequences, e.g. SEQ ID NO: 2, i.e. in the N-terminal, and/or the C-terminal ends thereof. The amino acids of such extensions, if any, are to be numbered as is usual in the art, i.e. for a C-terminal extension:  
35 189, 190, 191 and so forth, and for an N-terminal extension -1, -2, -3 and so forth

For each amino acid residue in each protease aligned to the reference sequence, e.g. SEQ ID NO: 2, as explained above (for the purposes of determining degree of identity), it is

possible to directly and unambiguously assign an amino acid residue in the reference sequence, e.g. SEQ ID NO: 2, to which it corresponds. Corresponding residues are assigned the same position, or number, by reference to, e.g., SEQ ID NO: 2.

For each amino acid residue in another protease, the corresponding position of the reference sequence, e.g. SEQ ID NO: 2, can be found, as follows:

The amino acid sequence of the other protease is designated SEQ X. A position corresponding to position N of SEQ ID NO: 2 is found as follows: SEQ X is aligned with SEQ ID NO: 2 as specified above. From the alignment, the position in sequence SEQ X corresponding to position N of SEQ ID NO: 2 can be clearly and unambiguously derived, using the principles described below.

SEQ X may be a mature part of the protease in question, or it may also include a signal peptide part, or it may be a fragment of the mature protease which has protease activity, e.g. a fragment of the same length as SEQ ID NO: 2, and/or it may be the fragment which extends from A1 to T188 when aligned with SEQ ID NO: 2 as described herein.

Three alignments are inserted below as Tables I, II and III. The alignments were prepared as described above, aligning the mature part of another protease (SEQ X1, SEQ X2, and SEQ X3, respectively) to SEQ ID NO: 2. Approximately 50 amino acid residues of each protease are shown.

Looking first at the alignment of Table I, it is clear that, e.g., G42 of SEQ ID NO: 2 corresponds to P42 of SEQ X1, as these residues are on top of each other in the alignment. They are both assigned number 42, viz. the number of the corresponding residue in SEQ ID NO: 2. It is also apparent from this alignment that, e.g., SEQ X1 does not comprise 10Y, but it does comprise 38T.

#### 25 Table I

ADIIGGLAYY	MGGRC	SVGFA	ATNSAGQPGF	VTAGHCGTVG	TGVTIGNGTG	SEQ ID NO: 2
ADIIGGLAYT	MGGRC	SVGFA	ATNSAGQPGF	VTAGHCGTVG	TPVSIGNGGG	SEQ X1
10	20	30	40	50		

Tables II and III are examples of alignments producing gaps in either of the two sequences.

In the alignment of Table II, a gap is produced in SEQ X2. The highlighted amino acid residue P of SEQ X2 is, for the present purposes, designated P28, although in SEQ X as *such* it is P25.

#### Table II

ADIIGGLAYY	MGGRC	SVGFA	ATNSAGQPGF	VTAGHCGTVG	TGVTIGNGTG	SEQ ID NO: 2
ADIIGGLAYT	MGGRC	SVGFA	ATNA---PGF	VTAGHCGTVG	TPVSI	SEQ X2
10	20	30	40	50		

In the alignment of Table III, a gap is produced in SEQ X3. When a gap is produced between amino acids having position number nn and (nn+1) of SEQ ID NO: 2, each position of the gap is assigned a lower case or subscript letter: a, b, c etc. to the former position number, i.e. nn. Accordingly, each position of the gap is numbered nna, nnb etc. The highlighted amino acid residue R of SEQ X3 is, for the present purposes, designated R33a, although in SEQ X3 as *such* it is R34.

### 10 Table III

ADIIGGLAYY	MGGRC	SVGFA	ATNSAGQPGF	VTA--GHC	GT	VGTPVTIGNGTG	SEQ ID NO: 2
ADIIGGLAYT	MGGRC	SVGFA	ATNASGQPGF	VTARSGHC	GT	VGTPVSI	SEQ X3
10	20	30	40	50			

In further particular embodiments of either aspect of the invention, the polypeptide of the invention has a melting temperature ( $T_m$ ) of at least 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or at least 95°C, as determined by Differential Scanning Calorimetry (DSC).

The DSC is performed in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0.

The scan rate is constant, e.g. 1.5°C/min.

The interval scanned may be from 20 to 100 °C.

20 There are no upper limitations on the  $T_m$ , however, it is presently contemplated that the  $T_m$  may be below 150°C, 145°C, 140°C, 135°C, 130°C, 125°C, 120°C, 115°C, 110°C, 105°C, or below 100°C.

In an alternative embodiment, another buffer is selected for the scanning, e.g. a buffer of pH 5.0, 5.5, 6.0, or pH 6.5.

25 In further alternative embodiments, a higher or lower scan rate may be used, e.g. a lower one of 1.4°C/min, 1.3°C/min, 1.2°C/min, 1.1°C/min, 1.0°C/min, or 0.9°C/min.

Reference is made to Example 2 for further details about the scanning procedure.

In a particular embodiment, the protease of the invention exhibits an amended temperature activity profile as compared to the protease derived from *Nocardiosis sp.* NRRL 18262. For example, the protease of the invention may exhibit a relative activity at pH 9 and 80°C of at least 0.40, preferably at least 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, or at least 0.95, the term "relative" referring to the maximum activity measured for the protease in question. For Protease 22, the L2a protease, as well as for the protease derived from *Nocardiosis dassonvillei subspecies dassonvillei* DSM 43235, the activity is relative to the activity at 80°C which is set to 1.000 (100%), and for Protease 8, and the

protease derived from *Nocardioopsis* sp. NRRL 18262, the activity at 70°C is set to 1.000 (100%), see Examples 2, 7, 8, and 9. As another example, the protease of the invention exhibits a relative activity at pH 9 and 90°C of at least 0.10, preferably at least 0.15, 0.20, 0.25, 0.30, or of at least 0.35. In a particular embodiment, the protease activity is measured  
5 using the Protazyme AK assay of Example 2.

A screening for thermostable proteases related to SEQ ID NOs: 2, 8, 10 or 12 of the invention may be performed as follows: Screening a DNA library with primers, e.g. either of SEQ ID NOs: 3 or 4, or preferably with the mature peptide encoding parts of either of SEQ ID NOs: 1, 7, 9 or 11; expressing the hybridizing clones in a suitable strain, e.g. a strain of  
10 *Bacillus* or *E. coli*. In a next step, the expressed proteases related to either of SEQ ID NOs: 2, 8, 10 and/or 12 are purified, preferably in a micro-purification process (see e.g. WO 03/037914), and the amount of active protease is determined for each candidate by use of the well-known principle of active site titration (AST) with a strong inhibitor of the enzyme. In a subsequent step, a known amount of the enzyme is then incubated at a desired elevated  
15 temperature, e.g. 85°C, for a desired time, e.g. 2 hours; and the residual protease activity is determined, e.g. by use of any of the protease assays described herein, for example the Protazyme AK assay of Example 2. The major part of the procedure may be automatized, and if desired performed with the assistance of robots. The verification of thermostability is e.g. done by purification of the protease, and establishment of  $T_m$  by DSC as described in the  
20 experimental part herein.

The present invention also relates to the animal feed use of the polypeptides of the invention.

The degree of identity between two amino acid sequences may also be determined by the Clustal method (Higgins, 1989, CABIOS 5: 151-153) using the LASERGENE™  
25 MEGALIGN™ software (DNASTAR, Inc., Madison, WI) with an identity table and the following multiple alignment parameters: Gap penalty of 10, and gap length penalty of 10. Pairwise alignment parameters are Ktuple=1, gap penalty=3, windows=5, and diagonals=5. The degree of identity between two nucleotide sequences may be determined using the same algorithm and software package as described above with the following settings: Gap  
30 penalty of 10, and gap length penalty of 10. Pairwise alignment parameters are Ktuple=3, gap penalty=3 and windows=20.

In a particular embodiment, the homologous polypeptides have an amino acid sequence that differs from amino acids 1 to 188 of SEQ ID NO: 2 or -166 to 188 of SEQ ID NO: 2, or from amino acids 1 to 196 of SEQ ID NO: 8 or -192 to 196 of SEQ ID NO: 8, by

35 (i) no more than 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 62, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, or no more than 20 amino acids;

(ii) no more than twenty, nineteen, eighteen, seventeen, sixteen, fifteen, fourteen, thirteen, twelve, or no more than eleven amino acids;

(iii) no more than ten, nine, eight, seven, six, five, four, three, two, or no more than one amino acid;

5 (iv) ten, or by nine, or by eight, or by seven, or by six, or by five amino acids; or

(v) four, or by three, or by two amino acids, or by one amino acid.

In a particular embodiment, the polypeptides of the present invention comprise the amino acid sequence of the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, or 12, or allelic variants thereof; or fragments thereof that have protease activity.

10 In another preferred embodiment, the polypeptides of the present invention consist of the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, or 12, or allelic variants thereof; or fragments thereof that have protease activity.

A fragment of the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, or 12 is a polypeptide having one or more amino acids deleted from the amino and/or carboxyl  
15 terminus of these amino acid sequences. In one embodiment a fragment contains at least 75 amino acid residues, or at least 100 amino acid residues, or at least 125 amino acid residues, or at least 150 amino acid residues, or at least 160 amino acid residues, or at least 165 amino acid residues, or at least 170 amino acid residues, or at least 175 amino acid residues.

20 An allelic variant denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

25 The present invention also relates to isolated polypeptides having protease activity and which are encoded by nucleic acid sequences which hybridize under very low, or low, or medium, or medium-high, or high, or very high stringency conditions with a nucleic acid probe which hybridizes under the same conditions with (a) nucleotides 499-1062 of SEQ ID NO: 1, nucleotides 577-1164 of SEQ ID NO: 7, nucleotides 586-1152 of SEQ ID NO: 9, and/or nucleotides 502-1065 of SEQ ID NO: 11; (b) a subsequence of (a), or (c) a  
30 complementary strand of (a), or (b) (J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor, New York). In one particular embodiment the nucleic acid probe is selected from amongst the nucleic acid sequences of (a), (b), or (c) above. The nucleotides of (a) correspond to the mature peptide  
35 encoding parts.

The subsequence of the nucleotides mentioned under (a) above may be at least 100 nucleotides, or in another embodiment at least 200 nucleotides. Moreover, the subsequence may encode a polypeptide fragment that has protease activity.

The nucleic acid sequences of (a) or (b) above, as well as the corresponding mature amino acid sequences of SEQ ID NOs: 2, 8, 10, or 12, or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding polypeptides having protease activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 35 nucleotides in length. Longer probes can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ , biotin, or avidin). Such probes are encompassed by the present invention.

Thus, a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA that hybridizes with the probes described above and which encodes a polypeptide having protease activity. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with either of SEQ ID NOs: 1, 7, 9, or 11, or a subsequence thereof, the carrier material is used in a Southern blot. For purposes of the present invention, hybridization indicates that the nucleic acid sequence hybridizes to a labeled nucleic acid probe corresponding to the sequences of (a), (b) or (c) above, under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions are detected using X-ray film.

In a particular embodiment, the nucleic acid probe is a nucleic acid sequence which encodes amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12, or subsequences thereof. In another embodiment, the nucleic acid probe is nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 (the mature polypeptide coding regions).

For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50%



formamide for high and very high stringencies, following standard Southern blotting procedures.

For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15 minutes using 0.2 x SSC, 0.2% SDS, 20% formamide preferably at least at 45°C (very low stringency), more preferably at least at 50°C (low stringency), more preferably at least at 55°C (medium stringency), more preferably at least at 60°C (medium-high stringency), even more preferably at least at 65°C (high stringency), and most preferably at least at 70°C (very high stringency).

For short probes about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at 5°C to 10°C below the calculated  $T_m$  using the calculation according to Bolton and McCarthy (1962, Proceedings of the National Academy of Sciences USA 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

For short probes about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated  $T_m$ .

The present invention also relates to variants of the polypeptide having an amino acid sequence of amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12, comprising a substitution, deletion, and/or insertion of one or more amino acids.

The amino acid sequences of the variant polypeptides may differ from the amino acid sequence of amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12, by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. In a particular embodiment, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino

acids (glycine, alanine, serine, threonine and methionine). Accordingly, for example, the invention relates to a polypeptide having, or comprising, a sequence as set forth in the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, or 12, wherein conservative amino acid substitutions comprise replacements, one for another, among the basic amino acids (arginine, lysine and histidine), among the acidic amino acids (glutamic acid and aspartic acid), among the polar amino acids (glutamine and asparagine), among the hydrophobic amino acids (alanine, leucine, isoleucine, and valine), among the aromatic amino acids (phenylalanine, tryptophan and tyrosine), and among the small amino acids (glycine, alanine, serine, threonine and methionine), or any combination thereof, or active fragments thereof.

Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, The Proteins, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

In a particular embodiment, the polypeptides of the invention and for use according to the invention are acid-stable. For the present purposes, the term acid-stable means that the residual activity after 2 hours of incubation at pH 2.0, pH 2.5 or pH 3.0 and 37°C, is at least 50%, as compared to the residual activity of a corresponding sample incubated for 2 hours at pH 9.0 and 5°C. In a particular embodiment, the residual activity is at least 60%, 70%, 80% or at least 90%. A suitable assay for determining acid-stability is the pH-stability assay of Example 2.

In another particular embodiment, the polypeptides of the invention and for use according to the invention have a relative activity at pH 7.0 of at least 0.10, 0.15, 0.20, 0.25, 0.30 or at least 0.35. The pH-profile test of Example 2 is used for the determination.

In still further particular embodiments, the polypeptides of the invention and for use according to the invention have i) a relative activity at 60°C and pH 9 of at least 0.05, 0.10, 0.15 or at least 0.19; and/or ii) a relative activity at 70°C of at least 0.40, 0.50, or at least 0.60. The temperature-profile test of Example 2 is used for these determinations.

The polypeptide of the invention and for use according to the invention may be a bacterial or fungal polypeptide. The fungal polypeptide may be derived from a filamentous fungus or from a yeast.

In particular embodiments, the polypeptide of the invention is i) a bacterial protease; ii) a protease of the phylum *Actinobacteria*; iii) of the class *Actinobacteria*; iv) of the order *Actinomycetales* v) of the family *Nocardiopsaceae*; vi) of the genus *Nocardiopsis*; and/or a protease derived from vii) *Nocardiopsis* species such as *Nocardiopsis alba*, *Nocardiopsis alkaliphila*, *Nocardiopsis antarctica*, *Nocardiopsis prasina*, *Nocardiopsis composta*, *Nocardiopsis exhalans*, *Nocardiopsis halophila*, *Nocardiopsis halotolerans*, *Nocardiopsis*

*kunsanensis*, *Nocardiopsis listeri*, *Nocardiopsis lucentensis*, *Nocardiopsis metallicus*, *Nocardiopsis synnemataformans*, *Nocardiopsis trehalosi*, *Nocardiopsis tropica*, *Nocardiopsis umidischolae*, *Nocardiopsis xinjiangensis*, or *Nocardiopsis dassonvillei*, for example *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235, *Nocardiopsis* sp. DSM 16424, or *Nocardiopsis alba* DSM 15647; such as a polypeptide with either of the mature amino acid sequences of SEQ ID NOs: 2, 8, 10, and 12. In a particular embodiment, the protease derives from *Nocardiopsis alba*, *Nocardiopsis antarctica*, or *Nocardiopsis dassonvillei*.

The above taxonomy is according to the chapter: The road map to the Manual by G.M. Garrity & J. G. Holt in Bergey's Manual of Systematic Bacteriology, 2001, second edition, volume 1, David R. Boone, Richard W. Castenholz.

It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.

Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

Furthermore, such polypeptides may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a genomic or cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, e.g., Sambrook et al., 1989, supra).

As defined herein, an "isolated" polypeptide is a polypeptide which is essentially free of other polypeptides, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.

Polypeptides encoded by nucleic acid sequences of the present invention also include fused polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides are known in the art, e.g. PCR, or ligating the

coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator.

In still further particular embodiments, the invention excludes one or more of the proteases derived from (i) *Nocardioopsis dassonvillei* NRRL 18133 which is disclosed in WO 88/03947; (ii) *Nocardioopsis* sp. strain OPC-210 (FERM P-10508) which is disclosed in JP 2-255081-A ; (iii) strain ZIMET 43647 of the species *Nocardioopsis dassonvillei* which is disclosed in DD 200432[8]; (iv) *Nocardioopsis* sp. TOA-1 (FERM-P-18676), which is disclosed in JP 2003284571; and/or (v) the corresponding DNA.

### Nucleic Acid Sequences

10 The present invention also relates to isolated nucleic acid sequences that encode a polypeptide of the present invention. Particular nucleic acid sequences of the invention are nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11; corresponding to the mature polypeptide encoding regions of SEQ ID NOs: 2, 8, 10, and 12, respectively. The present invention also  
15 encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence of the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, and 12, but which differ from the corresponding parts of SEQ ID NOs: 1, 7, 9, and 11, respectively, by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NOs: 1, 7, 9, and 11, which encode fragments of SEQ ID NOs: 2, 8, 10, and 12,  
20 respectively, which have protease activity.

A subsequence of SEQ ID NOs: 1, 7, 9, and 11, is a nucleic acid sequence encompassed by SEQ ID NOs: 1, 7, 9, and 11, respectively, except that one or more nucleotides from the 5' and/or 3' end has been deleted. Preferably, a subsequence contains at least 225 nucleotides, more preferably at least 300 nucleotides, even more preferably at  
25 least 375, 450, 500, 531, 600, 700, 800, 900 or 1000 nucleotides.

The present invention also relates to nucleotide sequences which have a degree of identity to nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%. In particular  
30 embodiments, the degree of identity to either of these nucleotides is at least 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99%.

The present invention also relates to mutant nucleic acid sequences comprising at least one mutation in the mature peptide encoding parts of either of SEQ ID NOs: 1, 7, 9, or 11, in which the mutant nucleic acid sequence encodes a polypeptide which (i) consists of  
35 the mature peptide parts of either of SEQ ID NOs: 2, 8, 10, and 12, respectively, or (ii) is a variant of any of the sequences of (i), wherein the variant comprises a substitution, deletion,

and/or insertion of one or more amino acids, or (iii) is an allelic variant of any of the sequences of (i), or (iv) is a fragment of any of the sequences of (i).

The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from  
5 cDNA, or a combination thereof. The cloning of the nucleic acid sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, PCR: A Guide to  
10 Methods and Application, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be cloned from a strain of *Nocardiosis* or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.

15 The term "isolated nucleic acid sequence" as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis. For example, an isolated nucleic acid sequence can  
20 be obtained by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where  
25 multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

Modification of a nucleic acid sequence encoding a polypeptide of the present invention may be necessary for the synthesis of polypeptides substantially similar to the  
30 polypeptide. The term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source, e.g., variants that differ in specific activity, thermostability, pH optimum, allergenicity, or the like. The variant sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding  
35 part of SEQ ID NOs: 1, 7, 9 and/or 11, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which correspond to the codon usage

of the host organism intended for production of the protease, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, Protein Expression and Purification 2: 95-107. Low-allergenic polypeptides can e.g. be prepared as described above.

5 It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-  
10 directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for protease activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-protease interaction can also be determined by analysis of the three-  
15 dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, Science 255: 306-312; Smith et al., 1992, Journal of Molecular Biology 224: 899-904; Wlodaver et al., 1992, FEBS Letters 309: 59-64).

The present invention also relates to isolated nucleic acid sequences encoding a  
20 polypeptide of the present invention, which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with a nucleic acid probe which hybridizes under the same conditions with the nucleic acid sequence, preferably the  
25 mature peptide encoding part, of either of SEQ ID NOs: 1, 7, 9, or 11, or their complementary strands; or allelic variants and subsequences thereof (Sambrook et al., 1989, supra), as defined herein.

The present invention also relates to isolated nucleic acid sequences produced by (a) hybridizing a DNA under very low, low, medium, medium-high, high, or very high stringency  
30 conditions with (i) nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11, (ii) a subsequence of (i), or (iii) a complementary strand of (i), or (ii); and (b) isolating the nucleic acid sequence. The subsequence is preferably a sequence of at least 100 nucleotides such as a sequence that encodes a polypeptide fragment which has protease activity.

35

#### Methods for Producing Mutant Nucleic Acid Sequences

The present invention further relates to methods for producing a mutant nucleic acid sequence, comprising introducing at least one mutation into the mature polypeptide coding sequence of either of SEQ ID NOs: 1, 7, 9, or 11, or a subsequence thereof, wherein the mutant nucleic acid sequence encodes a polypeptide which consists of the mature peptides of either of SEQ ID NOs: 2, 8, 10, or 12, respectively; or a fragment thereof which has protease activity.

The introduction of a mutation into the nucleic acid sequence to exchange one nucleotide for another nucleotide may be accomplished by site-directed mutagenesis using any of the methods known in the art. Particularly useful is the procedure that utilizes a supercoiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. The oligonucleotide primers, each complementary to opposite strands of the vector, extend during temperature cycling by means of *Pfu* DNA polymerase. On incorporation of the primers, a mutated plasmid containing staggered nicks is generated. Following temperature cycling, the product is treated with *DpnI* which is specific for methylated and hemimethylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA. Other procedures known in the art may also be used.

### Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence of the present invention operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences. Expression will be understood to include any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

"Nucleic acid construct" is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid combined and juxtaposed in a manner that would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding sequence" is defined herein as a nucleic acid sequence that directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by a ribosome binding site (prokaryotes) or by the ATG start codon (eukaryotes) located just upstream of the open reading frame at the 5' end of the mRNA and a transcription terminator sequence located just downstream of the open reading frame at the



3' end of the mRNA. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

An isolated nucleic acid sequence encoding a polypeptide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide.

5 Manipulation of the nucleic acid sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing recombinant DNA methods are well known in the art.

The term "control sequences" is defined herein to include all components that are necessary or advantageous for the expression of a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide. The term "operably linked" is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the coding sequence of the DNA sequence such that the control sequence directs the expression of a polypeptide.

20 The control sequence may be an appropriate promoter sequence, a nucleic acid sequence that is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcriptional control sequences that mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the *E. coli* lac operon, *Streptomyces coelicolor* agarase gene (dagA), *Bacillus subtilis* levansucrase gene (sacB), *Bacillus licheniformis* alpha-amylase gene (amyL), *Bacillus stearothermophilus* maltogenic amylase gene (amyM), *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ), *Bacillus licheniformis* penicillinase gene (penP), *Bacillus subtilis* xylA and xylB genes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75: 3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.

Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (glaA), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, and *Fusarium oxysporum* trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, *Yeast* 8: 423-488.

The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, *supra*.

Preferred terminators for bacterial host cells, such as a *Bacillus* host cell, are the terminators from *Bacillus licheniformis* alpha-amylase gene (amyL), the *Bacillus stearothermophilus* maltogenic amylase gene (amyM), or the *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ).

The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleic acid sequence encoding the polypeptide.

Any leader sequence that is functional in the host cell of choice may be used in the present invention.

Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

5        Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

10        The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

15        Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-like protease, and *Aspergillus niger* alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983-5990.

20        The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the  
25        secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the  
30        polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

Effective signal peptide coding regions for bacterial host cells are the signal peptide coding regions obtained from the genes for *Bacillus* NCIB 11837 maltogenic amylase,  
35        *Bacillus stearothermophilus* alpha-amylase, *Bacillus licheniformis* subtilisin, *Bacillus licheniformis* alpha-amylase, *Bacillus stearothermophilus* neutral proteases (nprT, nprS,

nprM), and *Bacillus subtilis* prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.

Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* cellulase, and *Humicola lanuginosa* lipase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.

The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for *Bacillus subtilis* alkaline protease (aprE), *Bacillus subtilis* neutral protease (nprT), *Saccharomyces cerevisiae* alpha-factor, *Rhizomucor miehei* aspartic proteinase, and *Myceliophthora thermophila* laccase (WO 95/33836).

In a preferred embodiment, the propeptide coding region is nucleotides 1-498 of SEQ ID NO: 1 which encode amino acids -166 to -1 of SEQ ID NO: 2, nucleotides 82-576 of SEQ ID NO: 7 which encode amino acids -165 to -1 of SEQ ID NO: 8, nucleotides 88-585 of SEQ ID NO: 9 which encode amino acids -166 to -1 of SEQ ID NO: 10, and nucleotides 1-501 of SEQ ID NO: 11 which encode amino acids -167 to -1 of SEQ ID NO: 12.

In a preferred embodiment, the signal peptide coding region is nucleotides 1-81 of SEQ ID NO: 7 which encode amino acids 1-29 of SEQ ID NO: 8, or nucleotides 1-87 of SEQ ID NO: 9 which encode amino acids 1-29 of SEQ ID NO: 10.

Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of

regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be operably linked with the regulatory sequence.

### Expression Vectors

The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a

filamentous fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hygB* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), *trpC* (anthranilate synthase), as well as equivalents thereof.

- 5 Preferred for use in an *Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygroscopicus*.

The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

- 10 For integration into the host cell genome, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional
- 15 nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding
- 20 target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

- 25 For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM $\beta$ 1 permitting replication in *Bacillus*. Examples of origins of replication for use in a
- 30 yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes it functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75: 1433).

- More than one copy of a nucleic acid sequence of the present invention may be
- 35 inserted into the host cell to increase production of the gene product. An increase in the copy number of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable

marker gene with the nucleic acid sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleic acid sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, *supra*).

The protease may also be co-expressed together with at least one other enzyme of interest for animal feed, such as alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6).

The enzymes may be co-expressed from different vectors, from one vector, or using a mixture of both techniques. When using different vectors, the vectors may have different selectable markers, and different origins of replication. When using only one vector, the genes can be expressed from one or more promoters. If cloned under the regulation of one promoter (di- or multi-cistronic), the order in which the genes are cloned may affect the expression levels of the proteins. The protease may also be expressed as a fusion protein, i.e. that the gene encoding the protease has been fused in frame to the gene encoding another protein. This protein may be another enzyme or a functional domain from another enzyme.

### Host Cells

The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a nucleic acid sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote.

Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, or a *Streptomyces* cell, or cells of lactic acid bacteria; or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. Lactic acid bacteria include, but are



not limited to, species of the genera *Lactococcus*, *Lactobacillus*, *Leuconostoc*, *Streptococcus*, *Pediococcus*, and *Enterococcus*.

The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168: 111-115), using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, Journal of Molecular Biology 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169: 5771-5278).

The host cell may be a eukaryote, such as a non-human animal cell, an insect cell, a plant cell, or a fungal cell.

In one particular embodiment, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., in Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra).

In another particular embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporeogenous yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F.A., Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980).

The yeast host cell may be a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

The fungal host cell may be a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

Examples of filamentous fungal host cells are cells of species of, but not limited to, *Acremonium*, *Aspergillus*, *Fusarium*, *Humicola*, *Mucor*, *Myceliophthora*, *Neurospora*, *Penicillium*, *Thielavia*, *Tolypocladium*, or *Trichoderma*.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*.

Suitable procedures for transformation of *Aspergillus* host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier et al., 1989, *Gene* 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153: 163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75: 1920.

## 10 Methods of Production

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a strain, which in its wild-type form is capable of producing the polypeptide; and (b) recovering the polypeptide. Preferably, the strain is of the genus *Nocardiopsis*, more preferably *Nocardiopsis dassonvillei*, *Nocardiopsis alba*, or  
15 *Nocardiopsis antarctica*, more preferably *Nocardiopsis dassonvillei* subsp. *dassonvillei*.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide, wherein the host cell comprises a mutant nucleic acid sequence comprising at least one mutation in nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11, in which the mutant nucleic acid sequence encodes a polypeptide which (i) consists of amino acids 1 to 188 of SEQ ID  
20 NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12, or (ii) is a variant of any of the sequences of (i), wherein the variant comprises a substitution, deletion, and/or insertion of one or more amino acids, or (iii) is an allelic variant of any of the sequences of (i), or (iv) is a fragment of any of the sequences of (i).

In the production methods of the present invention, the cells are cultivated in a  
30 nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a  
35 suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type

Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of a product, or disappearance of a substrate. For example, a protease assay may be used to determine the activity of the polypeptide as described herein.

The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

## Plants

The present invention also relates to a transgenic plant, plant part, or plant cell which has been transformed with a nucleic acid sequence encoding a polypeptide having protease activity of the present invention so as to express and produce the polypeptide in recoverable quantities. The polypeptide may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the recombinant polypeptide may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

In a particular embodiment, the polypeptide is targeted to the endosperm storage vacuoles in seeds. This can be obtained by synthesizing it as a precursor with a suitable signal peptide, see Horvath et al in PNAS, Feb. 15, 2000, vol. 97, no. 4, p. 1914-1919.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot) or engineered variants thereof. Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *Festuca*, *Lolium*, temperate grass, such as *Agrostis*, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, triticale (stabilized hybrid of wheat (*Triticum*) and rye (*Secale*), and maize (corn). Examples of dicot plants are tobacco, legumes, such as sunflower (*Helianthus*), cotton (*Gossypium*) lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*.

Low-phytate plants as described e.g. in US patent no. 5,689,054 and US patent no. 6,111,168 are examples of engineered plants.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers, as well as the individual tissues comprising these parts, e.g. epidermis, mesophyll, parenchyma, vascular tissues, meristems. Also specific plant cell compartments, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes, and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the utilisation of the invention are also considered plant parts, e.g. embryos, endosperms, aleurone and seed coats. Also included within the scope of the present invention are the progeny of such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing a polypeptide of the present invention may be constructed in accordance with methods known in the art. Briefly, the plant or plant cell is constructed by incorporating one or more expression constructs encoding a polypeptide of the present invention into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

Conveniently, the expression construct is a nucleic acid construct which comprises a nucleic acid sequence encoding a polypeptide of the present invention operably linked with appropriate regulatory sequences required for expression of the nucleic acid sequence in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences are determined, for example, on the basis of when, where, and how the polypeptide is desired to be expressed. For instance, the expression of the gene encoding a polypeptide of the present invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague et al., 1988, *Plant Physiology* 86: 506.

For constitutive expression, the following promoters may be used: The 35S-CaMV promoter (Franck et al., 1980, *Cell* 21: 285-294), the maize ubiquitin 1 (Christensen AH, Sharrock RA and Quail 1992. Maize polyubiquitin genes: structure, thermal perturbation of expression and transcript splicing, and promoter activity following transfer to protoplasts by electroporation), or the rice actin 1 promoter (*Plant Mo. Biol.* 18, 675-689.; Zhang W, McElroy D. and Wu R 1991, Analysis of rice Act1 5' region activity in transgenic rice plants. *Plant Cell* 3, 1155-1165). Organ-specific promoters may be, for example, a promoter from storage sink

tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990, Ann. Rev. Genet. 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994, Plant Mol. Biol. 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu et al., 1998, Plant and Cell Physiology 39: 885-889), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* (Conrad et al., 1998, Journal of Plant Physiology 152: 708-711), a promoter from a seed oil body protein (Chen et al., 1998, Plant and Cell Physiology 39: 935-941), the storage protein napA promoter from *Brassica napus*, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcS promoter from rice or tomato (Kyoizuka et al., 1993, Plant Physiology 102: 991-1000, the chlorella virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, Plant Molecular Biology 26: 85-93), or the aldP gene promoter from rice (Kagaya et al., 1995, Molecular and General Genetics 248: 668-674), or a wound inducible promoter such as the potato pin2 promoter (Xu et al., 1993, Plant Molecular Biology 22: 573-588). Likewise, the promoter may be inducible by abiotic treatments such as temperature, drought or alterations in salinity or inducible by exogenously applied substances that activate the promoter, e.g. ethanol, oestrogens, plant hormones like ethylene, abscisic acid, gibberellic acid, and/or heavy metals.

A promoter enhancer element may also be used to achieve higher expression of the protease in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding a polypeptide of the present invention. For instance, Xu et al., 1993, supra disclose the use of the first intron of the rice actin 1 gene to enhance expression.

Still further, the codon usage may be optimized for the plant species in question to improve expression (see Horvath et al referred to above).

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser et al., 1990, Science 244: 1293; Potrykus, 1990, Bio/Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).

Presently, *Agrobacterium tumefaciens*-mediated gene transfer is the method of choice for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, Plant Molecular Biology 19: 15-38), and it can also be used for transforming monocots, although other transformation methods are generally preferred for these plants. Presently, the method of choice for generating transgenic monocots, supplementing the *Agrobacterium*

approach, is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, Plant Journal 2: 275-281; Shimamoto, 1994, Current Opinion Biotechnology 5: 158-162; Vasil et al., 1992, Bio/Technology 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh et al., 1993, Plant Molecular Biology 21: 415-428.

Following transformation, the transformants having incorporated therein the expression construct are selected and regenerated into whole plants according to methods well-known in the art.

The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a nucleic acid sequence encoding a polypeptide having protease activity of the present invention under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

## Animals

The present invention also relates to a transgenic, non-human animal and products or elements thereof, examples of which are body fluids such as milk and blood, organs, flesh, and animal cells. Techniques for expressing proteins, e.g. in mammalian cells, are known in the art, see e.g. the handbook Protein Expression: A Practical Approach, Higgins and Hames (eds), Oxford University Press (1999), and the three other handbooks in this series relating to Gene Transcription, RNA processing, and Post-translational Processing. Generally speaking, to prepare a transgenic animal, selected cells of a selected animal are transformed with a nucleic acid sequence encoding a polypeptide having protease activity of the present invention so as to express and produce the polypeptide. The polypeptide may be recovered from the animal, e.g. from the milk of female animals, or the polypeptide may be expressed to the benefit of the animal itself, e.g. to assist the animal's digestion. Examples of animals are mentioned below in the section headed Animal Feed.

To produce a transgenic animal with a view to recovering the protease from the milk of the animal, a gene encoding the protease may be inserted into the fertilized eggs of an animal in question, e.g. by use of a transgene expression vector which comprises a suitable milk protein promoter, and the gene encoding the protease. The transgene expression vector is microinjected into fertilized eggs, and preferably permanently integrated into the chromosome. Once the egg begins to grow and divide, the potential embryo is implanted into a surrogate mother, and animals carrying the transgene are identified. The resulting animal can then be multiplied by conventional breeding. The polypeptide may be purified from the animal's milk, see e.g. Meade, H.M. et al (1999): Expression of recombinant proteins in the

milk of transgenic animals, Gene expression systems: Using nature for the art of expression. J. M. Fernandez and J. P. Hoeffler (eds.), Academic Press.

In the alternative, in order to produce a transgenic non-human animal that carries in the genome of its somatic and/or germ cells a nucleic acid sequence including a heterologous transgene construct including a transgene encoding the protease, the transgene may be operably linked to a first regulatory sequence for salivary gland specific expression of the protease, as disclosed in WO 00/064247.

### Compositions

In a still further aspect, the present invention relates to compositions comprising a polypeptide of the present invention.

The polypeptide compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the polypeptide composition may be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition may be stabilized in accordance with methods known in the art.

Examples are given below of preferred uses of the polypeptides or polypeptide compositions of the invention.

### Animal Feed

The present invention is also directed to methods for using the polypeptides of the invention in animal feed, as well as to feed compositions and feed additives comprising the polypeptides of the invention.

The term animal includes all animals, including human beings. Examples of animals are non-ruminants, and ruminants. Ruminant animals include, for example, animals such as sheep, goats, horses, and cattle, e.g. beef cattle, cows, and young calves. In a particular embodiment, the animal is a non-ruminant animal. Non-ruminant animals include monogastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, ducks and chicken (including but not limited to broiler chicks, layers); young calves; and fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and prawns).

The term feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal.

In the use according to the invention the protease can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred.

In a particular embodiment, the protease, in the form in which it is added to the feed, or when being included in a feed additive, is well-defined. Well-defined means that the



protease preparation is at least 50% pure as determined by Size-exclusion chromatography (see Example 12 of WO 01/58275). In other particular embodiments the protease preparation is at least 60, 70, 80, 85, 88, 90, 92, 94, or at least 95% pure as determined by this method.

5 A well-defined protease preparation is advantageous. For instance, it is much easier to dose correctly to the feed a protease that is essentially free from interfering or contaminating other proteases. The term dose correctly refers in particular to the objective of obtaining consistent and constant results, and the capability of optimising dosage based upon the desired effect.

10 For the use in animal feed, however, the protease need not be that pure; it may e.g. include other enzymes, in which case it could be termed a protease preparation.

The protease preparation can be (a) added directly to the feed (or used directly in a treatment process of proteins), or (b) it can be used in the production of one or more intermediate compositions such as feed additives or premixes that is subsequently added to the feed (or used in a treatment process). The degree of purity described above refers to the  
15 purity of the original protease preparation, whether used according to (a) or (b) above.

Protease preparations with purities of this order of magnitude are in particular obtainable using recombinant methods of production, whereas they are not so easily obtained and also subject to a much higher batch-to-batch variation when the protease is produced by traditional fermentation methods.

20 Such protease preparation may of course be mixed with other enzymes.

In a particular embodiment, the protease for use according to the invention is capable of solubilising proteins. A suitable assay for determining solubilised protein is disclosed in Example 3.

25 The protein may be an animal protein, such as meat and bone meal, and/or fish meal; or it may be a vegetable protein.

The term vegetable proteins as used herein refers to any compound, composition, preparation or mixture that includes at least one protein derived from or originating from a vegetable, including modified proteins and protein-derivatives. In particular embodiments, the protein content of the vegetable proteins is at least 10, 20, 30, 40, 50, or 60% (w/w).

30 Vegetable proteins may be derived from vegetable protein sources, such as legumes and cereals, for example materials from plants of the families *Fabaceae* (*Leguminosae*), *Cruciferaeae*, *Chenopodiaceae*, and *Poaceae*, such as soy bean meal, lupin meal and rapeseed meal.

35 In a particular embodiment, the vegetable protein source is material from one or more plants of the family *Fabaceae*, e.g. soybean, lupine, pea, or bean.

In another particular embodiment, the vegetable protein source is material from one or more plants of the family *Chenopodiaceae*, e.g. beet, sugar beet, spinach or quinoa.

Other examples of vegetable protein sources are rapeseed, sunflower seed, cotton seed, and cabbage.

Soybean is a preferred vegetable protein source.

Other examples of vegetable protein sources are cereals such as barley, wheat, rye, 5 oat, maize (corn), rice, triticale, and sorghum.

The treatment according to the invention of proteins with at least one protease of the invention results in an increased solubilisation of proteins.

The following are examples of % solubilised protein obtainable using the proteases of the invention in a monogastric *in vitro* model: At least 102%, 103%, 104%, 105%, 106%, or 10 at least 107%, relative to a blank. The percentage of solubilised protein is determined using the monogastric *in vitro* model of Example 3 and/or Example 10. The term solubilisation of proteins basically means bringing protein(s) into solution. Such solubilisation may be due to protease-mediated release of protein from other components of the usually complex natural compositions such as feed.

15 In a further particular embodiment, the protease for use according to the invention is capable of increasing the amount of digestible proteins. The following are examples of % digested or digestible protein obtainable using the proteases of the invention in a monogastric *in vitro* model: At least 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, or at least 116%, relative to a blank. The percentage of digested 20 or digestible protein is determined using the *in vitro* model of Example 3 and/or Example 10.

The following are examples of % digested or digestible protein obtainable using the proteases of the invention in an aquaculture *in vitro* model: At least 103%, 104%, 105%, 106%, 107%, 108%, 109% or at least 110%, relative to a blank. The percentage of digested or digestible protein is determined using the aquaculture *in vitro* model of Example 4.

25 In a still further particular embodiment, the protease for use according to the invention is capable of increasing the Degree of Hydrolysis (DH) of proteins. The following are examples of Degree of Hydrolysis increase obtainable in a monogastric *in vitro* model: At least 102%, 103%, 104%, 105%, 106%, or at least 107%, relative to a blank. The DH is determined using the monogastric *in vitro* model of Example 3. The following are examples 30 of Degree of Hydrolysis increase obtainable in an aquaculture *in vitro* model: At least 102%, 103%, 104%, 105%, 106%, or at least 107%, relative to a blank. The DH is determined using the aquaculture *in vitro* model of Example 4.

In a particular embodiment of a (pre-) treatment process of the invention, the protease(s) in question is affecting (or acting on, or exerting its solubilising influence on) the 35 proteins or protein sources. To achieve this, the protein or protein source is typically suspended in a solvent, e.g. an aqueous solvent such as water, and the pH and temperature values are adjusted paying due regard to the characteristics of the enzyme in question. For

example, the treatment may take place at a pH-value at which the activity of the actual protease is at least at least 40%, 50%, 60%, 70%, 80% or at least 90%. Likewise, for example, the treatment may take place at a temperature at which the activity of the actual protease is at least 40%, 50%, 60%, 70%, 80% or at least 90%. The above percentage activity indications are relative to the maximum activities. The enzymatic reaction is continued until the desired result is achieved, following which it may or may not be stopped by inactivating the enzyme, e.g. by a heat-treatment step.

In another particular embodiment of a treatment process of the invention, the protease action is sustained, meaning e.g. that the protease is added to the proteins or protein sources, but its solubilising influence is so to speak not switched on until later when desired, once suitable solubilising conditions are established, or once any enzyme inhibitors are inactivated, or whatever other means could have been applied to postpone the action of the enzyme.

In one embodiment the treatment is a pre-treatment of animal feed or proteins for use in animal feed.

The term improving the nutritional value of an animal feed means improving the availability and/or digestibility of the proteins, thereby leading to increased protein extraction from the diet components, higher protein yields, increased protein degradation and/or improved protein utilisation. The nutritional value of the feed is therefore increased, and the animal performance such as growth rate and/or weight gain and/or feed conversion ratio (i.e. the weight of ingested feed relative to weight gain) of the animal is/are improved.

In a particular embodiment the feed conversion ratio is increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or at least 10%. In a further particular embodiment the weight gain is increased by at least 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or at least 11%. These figures are relative to control experiments with no protease addition.

The feed conversion ratio (FCR) and the weight gain may be calculated as described in EEC (1986): Directive de la Commission du 9 avril 1986 fixant la méthode de calcul de la valeur énergétique des aliments composés destinés à la volaille. Journal Officiel des Communautés Européennes, L130, 53 – 54.

The protease can be added to the feed in any form, be it as a relatively pure protease, or in admixture with other components intended for addition to animal feed, i.e. in the form of animal feed additives, such as the so-called pre-mixes for animal feed.

In a further aspect the present invention relates to compositions for use in animal feed, such as animal feed, and animal feed additives, e.g. premixes.

Apart from the protease of the invention, the animal feed additives of the invention contain at least one fat-soluble vitamin, and/or at least one water soluble vitamin, and/or at least one trace mineral. The feed additive may also contain at least one macro mineral.

Further, optional, feed-additive ingredients are colouring agents, e.g. carotenoids such as beta-carotene, astaxanthin, and lutein; aroma compounds; stabilisers; antimicrobial peptides; polyunsaturated fatty acids; reactive oxygen generating species; and/or at least one other enzyme selected from amongst alpha-amylase (EC 3.2.1.1), phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4.-.-), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); amylase such as, for example, alpha-amylase (EC 3.2.1.1); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6).

In a particular embodiment these other enzymes are well-defined (as defined above for protease preparations).

Examples of antimicrobial peptides (AMP's) are CAP18, Leucocin A, Tiritpticin, Protegrin-1, Thanatin, Defensin, Lactoferrin, Lactoferricin, and Ovispirin such as Novispirin (Robert Lehrer, 2000), Plectasins, and Statins, including the compounds and polypeptides disclosed in WO 03/044049 and WO 03/048148, as well as variants or fragments of the above that retain antimicrobial activity.

Examples of antifungal polypeptides (AFP's) are the *Aspergillus giganteus*, and *Aspergillus niger* peptides, as well as variants and fragments thereof which retain antifungal activity, as disclosed in WO 94/01459 and WO 02/090384.

Examples of polyunsaturated fatty acids are C18, C20 and C22 polyunsaturated fatty acids, such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.

Examples of reactive oxygen generating species are chemicals such as perborate, persulphate, or percarbonate; and enzymes such as an oxidase, an oxygenase or a syntethase.

Usually fat- and water-soluble vitamins, as well as trace minerals form part of a so-called premix intended for addition to the feed, whereas macro minerals are usually separately added to the feed. A premix enriched with a protease of the invention, is an example of an animal feed additive of the invention.

In a particular embodiment, the animal feed additive of the invention is intended for being included (or prescribed as having to be included) in animal diets or feed at levels of 0.01 to 10.0%; more particularly 0.05 to 5.0%; or 0.2 to 1.0% (% meaning g additive per 100 g feed). This is so in particular for premixes.

The following are non-exclusive lists of examples of these components:

Examples of fat-soluble vitamins are vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3.

Examples of water-soluble vitamins are vitamin B12, biotin and choline, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. Ca-D-panthothenate.

Examples of trace minerals are manganese, zinc, iron, copper, iodine, selenium, and cobalt.

5        Examples of macro minerals are calcium, phosphorus and sodium.

The nutritional requirements of these components (exemplified with poultry and piglets/pigs) are listed in Table A of WO 01/58275. Nutritional requirement means that these components should be provided in the diet in the concentrations indicated.

10        In the alternative, the animal feed additive of the invention comprises at least one of the individual components specified in Table A of WO 01/58275. At least one means either of, one or more of, one, or two, or three, or four and so forth up to all thirteen, or up to all fifteen individual components. More specifically, this at least one individual component is included in the additive of the invention in such an amount as to provide an in-feed-concentration within the range indicated in column four, or column five, or column six of  
15    Table A.

The present invention also relates to animal feed compositions. Animal feed compositions or diets have a relatively high content of protein. Poultry and pig diets can be characterised as indicated in Table B of WO 01/58275, columns 2-3. Fish diets can be characterised as indicated in column 4 of this Table B. Furthermore such fish diets usually  
20    have a crude fat content of 200-310 g/kg. WO 01/58275 corresponds to US 09/779334 which is hereby incorporated by reference.

An animal feed composition according to the invention has a crude protein content of 50-800 g/kg, and furthermore comprises at least one protease as claimed herein.

25        Furthermore, or in the alternative (to the crude protein content indicated above), the animal feed composition of the invention has a content of metabolisable energy of 10-30 MJ/kg; and/or a content of calcium of 0.1-200 g/kg; and/or a content of available phosphorus of 0.1-200 g/kg; and/or a content of methionine of 0.1-100 g/kg; and/or a content of methionine plus cysteine of 0.1-150 g/kg; and/or a content of lysine of 0.5-50 g/kg.

30        In particular embodiments, the content of metabolisable energy, crude protein, calcium, phosphorus, methionine, methionine plus cysteine, and/or lysine is within any one of ranges 2, 3, 4 or 5 in Table B of WO 01/58275 (R. 2-5).

Crude protein is calculated as nitrogen (N) multiplied by a factor 6.25, i.e. Crude protein (g/kg) = N (g/kg) x 6.25. The nitrogen content is determined by the Kjeldahl method (A.O.A.C., 1984, Official Methods of Analysis 14th ed., Association of Official Analytical  
35    Chemists, Washington DC).

Metabolisable energy can be calculated on the basis of the NRC publication Nutrient requirements in swine, ninth revised edition 1988, subcommittee on swine nutrition,

committee on animal nutrition, board of agriculture, national research council. National Academy Press, Washington, D.C., pp. 2-6, and the European Table of Energy Values for Poultry Feed-stuffs, Spelderholt centre for poultry research and extension, 7361 DA Beekbergen, The Netherlands. Grafisch bedrijf Ponsen & Iooijen bv, Wageningen. ISBN 90-71463-12-5.

The dietary content of calcium, available phosphorus and amino acids in complete animal diets is calculated on the basis of feed tables such as Veevoedertabel 1997, gegevens over chemische samenstelling, verteerbaarheid en voederwaarde van voedermiddelen, Central Veevoederbureau, Runderweg 6, 8219 pk Lelystad. ISBN 90-72839-13-7.

In a particular embodiment, the animal feed composition of the invention contains at least one protein or protein source as defined above. It may also contain animal protein, such as Meat and Bone Meal, and/or Fish Meal, typically in an amount of 0-25%.

In still further particular embodiments, the animal feed composition of the invention contains 0-80% maize; and/or 0-80% sorghum; and/or 0-70% wheat; and/or 0-70% Barley; and/or 0-30% oats; and/or 0-40% soybean meal; and/or 0-25% fish meal; and/or 0-25% meat and bone meal; and/or 0-20% whey.

Animal diets can e.g. be manufactured as mash feed (non pelleted) or pelleted feed. Typically, the milled feed-stuffs are mixed and sufficient amounts of essential vitamins and minerals are added according to the specifications for the species in question. Enzymes can be added as solid or liquid enzyme formulations. For example, a solid enzyme formulation is typically added before or during the mixing step; and a liquid enzyme preparation is typically added after the pelleting step. The enzyme may also be incorporated in a feed additive or premix.

The final enzyme concentration in the diet is within the range of 0.01-200 mg enzyme protein per kg diet, for example in the range of 0.5-25 mg enzyme protein per kg animal diet.

The protease should of course be applied in an effective amount, i.e. in an amount adequate for improving solubilisation and/or improving nutritional value of feed. It is at present contemplated that the enzyme is administered in one or more of the following amounts (dosage ranges): 0.01-200; 0.01-100; 0.5-100; 1-50; 5-100; 10-100; 0.05-50; or 0.10-10 – all these ranges being in mg protease enzyme protein per kg feed (ppm).

For determining mg enzyme protein per kg feed, the protease is purified from the feed composition, and the specific activity of the purified protease is determined using a relevant assay (see under protease activity, substrates, and assays). The protease activity of the feed composition as such is also determined using the same assay, and on the basis of these two determinations, the dosage in mg enzyme protein per kg feed is calculated.

The same principles apply for determining mg enzyme protein in feed additives. Of course, if a sample is available of the protease used for preparing the feed additive or the feed, the specific activity is determined from this sample (no need to purify the protease from the feed composition or the additive).

5

### Detergent Compositions

The protease of the invention may be added to and thus become a component of a detergent composition.

The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the invention provides a detergent additive comprising the protease of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as another protease, such as alkaline proteases from *Bacillus*, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), e.g. from *H. lanuginosa* (*T. lanuginosus*) as described in EP 258068 and EP 305216 or from *H. insolens* as described in WO 96/13580; a *Pseudomonas* lipase, e.g. from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218272), *P. cepacia* (EP 331376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, e.g. from *B. subtilis* (Dartois et al. (1993), Biochemica et Biophysica Acta, 1131, 253-360), *B. stearothermophilus* (JP 64/744992) or *B. pumilus* (WO 91/16422). Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407225, EP 260105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202. Preferred commercially available lipase enzymes include Lipolase<sup>TM</sup> and Lipolase Ultra<sup>TM</sup> (Novozymes A/S). Suitable amylases (alpha- and/or beta-) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases



obtained from *Bacillus*, e.g. a special strain of *B. licheniformis*, described in more detail in GB 1,296,839. Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 95/26397, WO 96/23873, WO 97/43424, WO 00/60060, and WO 01/66712, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444. Commercially available amylases are Natalase<sup>TM</sup>, Supramyl<sup>TM</sup>, Stainzyme<sup>TM</sup>, Duramyl<sup>TM</sup>, Termamyl<sup>TM</sup>, Fungamyl<sup>TM</sup> and BAN<sup>TM</sup> (Novozymes A/S), Rapidase<sup>TM</sup> and Purastar<sup>TM</sup> (from Genencor International Inc.).

Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259. Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495257, EP 531372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544. Commercially available cellulases include Celluzyme<sup>TM</sup>, and Carezyme<sup>TM</sup> (Novozymes A/S), Clazinase<sup>TM</sup>, and Puradax HA<sup>TM</sup> (Genencor International Inc.), and KAC-500(B)<sup>TM</sup> (Kao Corporation).

Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include Guardzyme<sup>TM</sup> (Novozymes).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and

mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238216.

The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.

When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyltrimethylammoniumoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine ("glucamides").

The detergent may contain 0-65 % of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose, poly(vinylpyrrolidone), poly(ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H<sub>2</sub>O<sub>2</sub> source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

5 It is at present contemplated that in the detergent compositions any enzyme, in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-100 mg of enzyme protein per liter of wash liquor, preferably 0.05-5 mg of enzyme protein per liter of wash liquor, in particular 0.1-1 mg of enzyme protein per liter of wash liquor.

10 The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202.

### Deposit of Biological Material

The following biological materials have been deposited under the terms of the Budapest Treaty with the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany), and given the following accession numbers:

Deposit	Accession Number	Date of Deposit
<i>Nocardiopsis alba</i>	DSM 15647	May 30, 2003
<i>Nocardiopsis sp.</i>	DSM 16424	May 24, 2004

20 These strains have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122. The deposit represents a substantially pure culture of the deposited strain. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

25 *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 is publicly available from DSMZ. It was also deposited at other depositary institutions as follows: ATCC 23219, IMRU 30 1250, NCTC 10489.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the

appended claims. In the case of conflict, the present disclosure including definitions will control.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

5

## EXAMPLES

### EXAMPLE 1: Cloning and expression of the protease from *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235

#### 10 Reagents and media

LB agar Described in Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995

LB-PG agar LB agar supplemented with 0.5% Glucose and 0.05 M potassium phosphate, pH 7.0

15 PS-1 10% sucrose, 4% soybean flour, 1%  $\text{Na}_3\text{PO}_4 \cdot 12\text{H}_2\text{O}$ , 0.5%  $\text{CaCO}_3$ , and 0.01% pluronic acid

TE 10 mM Tris-HCl, pH 7.4

1 mM EDTA, pH 8.0

TEL 50 mg/ml Lysozym in TE-buffer

20 Thiocyanate 5M guanidium thiocyanate

100 mM EDTA

0.6 % w/v N-laurylsarcosine, sodium salt

60 g thiocyanate, 20 ml 0.5 M EDTA, pH 8.0, 20 ml  $\text{H}_2\text{O}$  dissolves at 65°C. Cool down to room temperature (RT) and add 0.6 g N-laurylsarcosine. Add  $\text{H}_2\text{O}$  to 100 ml and filter it

25 through a 0.2  $\mu$  sterile filter.

$\text{NH}_4\text{Ac}$  7.5 M  $\text{CH}_3\text{COONH}_4$

TER 1  $\mu\text{g/ml}$  Rnase A in TE-buffer

CIA Chloroform/isoamyl alcohol 24:1

#### 30 Experimental procedure

SEQ ID NO: 1 is the DNA sequence encoding a proform of the protease from *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235. Nucleotides 499-1062 corresponds to the mature peptide encoding part.

35 SEQ ID NO: 2 is the deduced amino acid sequence of SEQ ID NO: 1. Amino acids -166 to -1 is the propeptide, and amino acids 1 to 188 the mature peptide.

Cloning of SEQ ID NO: 1

The wild type was grown for 3 days before harvest in the following medium at 30°C:

Trypticase 20 g  
 Yeast extract 5 g  
 5 Ferrochloride 6 mg  
 Magnesiumsulfate 15 mg  
 Distilled water ad 1000 ml  
 pH was adjusted to 7.2 by addition of sodium hydroxide

10 Genomic DNA from *Nocardioopsis dassonvillei subsp. dassonvillei* DSM 43235 was isolated according to the following procedure:

1. Harvest 1.5 ml culture and resuspend in 100 µl TEL. Incubate at 37°C for 30 min.
2. Add 500 µl thiocyanate buffer and leave at room temperature for 10 min.
3. Add 250 µl NH<sub>4</sub>Ac and leave at ice for 10 min.
- 15 4. Add 500 µl CIA and mix.
5. Transfer to a microcentrifuge and spin for 10 min. at full speed.
6. Transfer supernatant to a new Eppendorf tube and add 0.54 volume cold isopropanol. Mix thoroughly.
7. Spin and wash the DNA pellet with 70 % EtOH.
- 20 8. Resuspend the genomic DNA in 100 µl TER.

The genomic DNA was used as template for PCR amplification using below primers SEQ ID NOS. 3 and 4. The PCR fragment was isolated on a 0.7% agarose gel and digested with restriction enzymes Cla I and BamH I. Primer 1565 (SEQ ID NO: 4) disrupts a BamH I site by changing an arginine codon from CGG to AGA and introduces a new BamH I site downstream from the stop codon.

Primers:

- 1423: 5'-GCT TTT AGT TCA TCG ATC GCA TCG GCT GCT CCG GCC CCC GTC CCC CAG-3' (SEQ ID NO: 3)
- 30 1565: 5'- GCG GAT CCT ATT AGG TTC TGA TCC TGA CAC CCC AG-3' (SEQ ID NO: 4)

The digested and purified PCR fragment was ligated to the Cla I and BamH I digested plasmid pDG268NeoMCS-PrmyQ/PrCRYIII/cryIIIAstab/Sav (United States Patent: 5,955,310).

The ligation mixture was used for transformation into *E. coli* TOP10F' (Invitrogen BV, The Netherlands) and several colonies were selected for miniprep (QIAprep spin, QIAGEN GmbH, Germany). The purified plasmids were checked for insert before transformation into a strain of *Bacillus subtilis* derived from *B. subtilis* DN 1885 with disrupted apr, npr and poi genes (Diderichsen et al (1990), J. Bacteriol., 172, 4315-4321). The disruption was performed essentially as described in "*Bacillus subtilis* and other Gram-Positive Bacteria,"

American Society for Microbiology, p.618, eds. A.L. Sonenshein, J.A. Hoch and Richard Losick (1993). Transformed cells were plated on 1% skim milk LB-PG agar plates, supplemented with 6  $\mu$ g/ml chloramphenicol. The plated cells were incubated over night at 37°C and protease containing colonies were identified by a surrounding clearing zone.

- 5 Protease positive colonies were selected and the coding sequence of the expressed enzyme from the expression construct was confirmed by DNA sequence analysis.

#### Fermentation

- 10 The *Bacillus subtilis* host cell transformed as described above was fermented on a rotary shaking table (250 r.p.m.) in 500 ml baffled Erlenmeyer flasks containing 100 ml PS-1 medium supplemented with 6  $\mu$ g/ml chloramphenicol, at 37°C for 16 hours and at 26°C for extra 4 days.

#### **EXAMPLE 2: Purification and characterization of the protease from *Nocardioopsis dassonvillei* subsp. *dassonvillei* DSM 43235**

##### Protease assays

###### 1) pNA assay:

pNA substrate : Suc-AAPF-pNA (Bachem L-1400).

Temperature : Room temperature (25°C)

- 20 Assay buffers : 100mM succinic acid, 100mM HEPES, 100mM CHES, 100mM CABS, 1mM CaCl<sub>2</sub>, 150mM KCl, 0.01% Triton X-100 adjusted to pH-values 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, and 12.0 with HCl or NaOH.

- 25 20 $\mu$ l protease (diluted in 0.01% Triton X-100) is mixed with 100 $\mu$ l assay buffer. The assay is started by adding 100 $\mu$ l pNA substrate (50mg dissolved in 1.0ml DMSO and further diluted 45x with 0.01% Triton X-100). The increase in OD<sub>405</sub> is monitored as a measure of the protease activity.

###### 2) Protazyme AK assay:

Substrate : Protazyme AK tablet (cross-linked and dyed casein; from Megazyme)

- 30 Temperature : controlled (assay temperature).

Assay buffers : 100mM succinic acid, 100mM HEPES, 100mM CHES, 100mM CABS, 1mM CaCl<sub>2</sub>, 150mM KCl, 0.01% Triton X-100 adjusted to pH-values 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0 with HCl or NaOH.

- 35 A Protazyme AK tablet is suspended in 2.0ml 0.01% Triton X-100 by gentle stirring. 500 $\mu$ l of this suspension and 500 $\mu$ l assay buffer are mixed in an Eppendorf tube and placed on ice. 20 $\mu$ l protease sample (diluted in 0.01% Triton X-100) is added. The assay is initiated by transferring the Eppendorf tube to an Eppendorf thermomixer, which is set to the assay

temperature. The tube is incubated for 15 minutes on the Eppendorf thermomixer at its highest shaking rate (1400 rpm). The incubation is stopped by transferring the tube back to the ice bath. Then the tube is centrifuged in an icecold centrifuge for a few minutes and 200µl supernatant is transferred to a microtiter plate. OD<sub>550</sub> is read as a measure of protease activity. A buffer blind is included in the assay (instead of enzyme).

#### Experimental procedure

The protease fermentation described in Example 1 was centrifuged (20000 x g, 20 min) and the supernatants were carefully decanted from the precipitates. The combined supernatants were filtered through a Seitz EKS plate in order to remove the rest of the *Bacillus* host cells. The EKS filtrate was transferred to 50mM H<sub>3</sub>BO<sub>3</sub>, 5mM succinic acid, 1mM CaCl<sub>2</sub>, pH7 on a G25 sephadex column and applied to a bacitracin silica column equilibrated in the same buffer. After washing the column extensively with the equilibration buffer, the protease was step-eluted with 100mM H<sub>3</sub>BO<sub>3</sub>, 10mM succinic acid, 2mM CaCl<sub>2</sub>, 1M NaCl, 25% isopropanol, pH7. The bacitracin eluate was transferred to 50mM H<sub>3</sub>BO<sub>3</sub>, 10mM CH<sub>3</sub>COOH, 1mM CaCl<sub>2</sub>, pH 4.5 and applied to a S sepharose HP column equilibrated in the same buffer. After washing the column extensively with the equilibration buffer, the protease was eluted with a linear NaCl gradient (0 → 0.5M) in the same buffer. Fractions from the column were analysed for protease activity (using the Protazyme AK assay at 37°C and pH 9) and active fractions were further analysed by SDS-PAGE. Fractions, where only one band was seen on the coomassie stained SDS-PAGE gel, were pooled as the purified preparation and was used for further characterization.

#### pH-activity, pH-stability, and temperature-activity

The pNA assay was used for obtaining the pH-activity profile as well as the pH-stability profile. For the pH-stability profile the protease was diluted 10x in the assay buffers and incubated for 2 hours at 37°C. After incubation the protease samples were transferred to the same pH - pH 9, before assay for residual activity, by dilution in the pH 9 assay buffer. The Protazyme AK assay was used for obtaining the temperature-activity profile at pH 9. The results are shown in Tables 1-3 below.



Table 1: pH-activity profile

pH	Protease derived from <i>Nocardioptis dassonvillei</i> subsp. <i>dassonvillei</i> DSM 43235	Protase derived from <i>Nocardioptis</i> sp. NRRL 18262
2	0.00	-
3	0.00	0.00
4	0.03	0.02
5	0.11	0.07
6	0.21	0.21
7	0.37	0.44
8	0.71	0.67
9	0.97	0.88
10	1.00	1.00
11	0.94	0.93

Table 2: pH-stability profile

pH	Protease derived from <i>Nocardioptis dassonvillei</i> subsp. <i>dassonvillei</i> DSM 43235	Protase derived from <i>Nocardioptis</i> sp. NRRL 18262
2.0	1.00	0.78
2.5	0.95	1.00
3.0	0.97	1.03
3.5	1.01	0.98
4.0	0.98	0.99
5.0	0.97	1.02
6.0	0.98	1.00
7.0	0.96	1.01
8.0	0.99	0.98
9.0	0.99	0.99
10.0	0.96	0.99
11.0	0.94	0.86
12.0	0.84	-
9.0 and after 2 hours at 5 °C	1.00	1.00

Table 3: Temperature activity profile

Temperature (°C)	Protease derived from <i>Nocardiopsis dassonvillei</i> subsp. <i>dassonvillei</i> DSM 43235	Protease derived from <i>Nocardiopsis</i> sp. NRRL 18262
15	0.08	0.02
25	0.01	0.02
37	0.03	0.07
50	0.09	0.20
60	0.19	0.51
70	0.63	1.00
80	1.00	0.39
90	0.35	-

Differential Scanning Calorimetry (DSC)

DSC was used to determine temperature stability at pH 7.0 of the proteases derived from *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 and from *Nocardiopsis* sp. NRRL 18262. Purified proteases were dialysed over night at 4°C against 10 mM sodium phosphate, 50 mM sodium chloride, pH 7.0 and run on a VP-DSC instrument (Micro Cal) with a constant scan rate of 1.5°C/min from 20 to 100°C. Data-handling was performed using the MicroCal Origin software.

The resulting denaturation or melting temperatures,  $T_m$ 's, were: For the protease of the invention derived from *Nocardiopsis dassonvillei* subsp. *dassonvillei*: 83.0°C; for the protease derived from *Nocardiopsis* sp. NRRL 18262: 76.5°C.

Other characteristics

The protease was found to be inhibited by Phenyl Methyl Sulfonyl Fluoride. Its relative molecular weight as determined by SDS-PAGE was  $M_r = 20\text{kDa}$ , and the N-terminal sequence: ADIIGGLAYYMGGRC.

### EXAMPLE 3: Performance of the *Nocardiopsis dassonvillei* subspecies *dassonvillei* DSM 43235 protease in a monogastric *in vitro* digestion model

The performance of a purified preparation of the mature part of the protease having SEQ ID NO: 2 (prepared as described in Examples 1 and 2) was tested in an *in vitro* model simulating the digestion in monogastric animals. In particular, the protease was tested for its ability to improve solubilisation and digestion of maize/-SBM (maize/-soybean meal) proteins. In the tables below, this protease is designated "protease of the invention." The *in vitro* system consisted of 15 flasks in which maize/-SBM substrate was initially incubated with HCl/pepsin - simulating gastric digestion - and subsequently with pancreatin - simulating intestinal digestion. 10 of the flasks were dosed with the protease at the start of the gastric phase whereas the remaining flasks served as blanks. At the end of the intestinal incubation

phase samples of *in vitro* digesta were removed and analysed for solubilised and digested protein.

#### Outline of *in vitro* digestion procedure

Components added	pH	Temperature	Time course	Simulated digestion phase
10 g maize/-SBM substrate (6:4), 41 ml HCl (0.105M)	3.0	40°C	t=0 min	Mixing
5 ml HCl (0.105M) / pepsin (3000 U/g substrate), 1 mL protease of the invention	3.0	40°C	t=30 min	Gastric digestion
16 ml H <sub>2</sub> O	3.0	40°C	t= 1.0 hour	Gastric digestion
7 ml NaOH (0,39M)	6.8	40°C	t=1.5 hours	Intestinal digestion
5 ml NaHCO <sub>3</sub> (1M) / pancreatin (8 mg/g diet)	6.8	40°C	t=2.0 hours	Intestinal digestion
Terminate incubation	7.0	40°C	t=6.0 hours	

5

#### Conditions

Substrate: 4 g SBM, 6 g maize (premixed)  
 pH: 3.0 stomach step/ 6.8-7.0 intestinal step  
 HCl: 0.105 M for 1.5 hours (i.e. 30 min HCl-substrate premixing)  
 10 pepsin: 3000 U /g diet for 1 hour  
 pancreatin: 8 mg/g diet for 4 hours  
 temperature: 40°C.  
 Replicates: 5

#### Solutions

0.39 M NaOH  
 0.105 M HCl  
 0.105 M HCl containing 6000 U pepsin per 5 ml  
 1 M NaHCO<sub>3</sub> containing 16 mg pancreatin per ml  
 20 125 mM NaAc-buffer, pH 6.0

#### Enzyme protein determinations

The amount of protease enzyme protein (in what follows, Enzyme Protein is abbreviated EP) is calculated on the basis of the  $A_{280}$  values and the amino acid sequences (amino acid compositions) using the principles outlined in S.C.Gill & P.H. von Hippel,  
 25 Analytical Biochemistry 182, 319-326, (1989).

#### Experimental procedure for *in vitro* model

The experimental procedure was according to the above outline. pH was measured at  
 30 time 1, 2.5, and 5.5 hours. Incubations were terminated after 6 hours and samples of 30 ml were removed and placed on ice before centrifugation (10000 x g, 10 min, 4°C). Supernatants were removed and stored at -20°C.

### Analysis

All samples were analysed for % degree of protein with the OPA method as well as content of solubilised and digested protein using gel filtration.

#### 5 DH determination by the OPA-method

The Degree of Hydrolysis (DH) of protein in different samples was determined using an semi-automated microtiter plate based colorimetric method (Nielsen,P.M.; Petersen,D.; Dambmann,C. Improved method for determining food protein degree of hydrolysis. J.Food Sci. 2001, 66, 642-646). The OPA reagent was prepared as follows: 7.620 g di-Na  
10 tetraborate decahydrate and 200 mg sodiumdodecyl sulphate (SDS) were dissolved in 150 ml deionized water. The reagents were completely dissolved before continuing. 160 mg o-phthal-dialdehyde 97% (OPA) was dissolved in 4 ml ethanol. The OPA solution was transferred quantitatively to the above-mentioned solution by rinsing with deionized water. 176 mg dithiothreitol 99% (DTT) was added to the solution that was made up to 200 ml with  
15 deionized water. A serine standard (0.9516 meqv/l) was prepared by solubilising 50 mg serine (Merck, Germany) in 500 ml deionized water.

The sample solution was prepared by diluting each sample to an absorbance (280 nm) of about 0.5. Generally, supernatants were diluted (100 ×) using an automated Tecan dilution station (Männedorf, Switzerland). All other spectrophotometer readings were  
20 performed at 340 nm using deionized water as the control. 25 µl of sample, standard and blind was dispensed into a microtiter plate. The micro-titer plate was inserted into an iEMS MF reader (Labsystems, Finland) and 200µl of OPA reagent was automatically dispensed. Plates were shaken (2 min; 700 rpm) before measuring absorbance. Finally, the DH was calculated. Eightfold determination of all samples was carried out.

25

#### Estimation of solubilised and digested protein

The content of solubilised protein in supernatants from *in vitro* digested samples was estimated by quantifying crude protein (CP) using gel filtration HPLC. Supernatants were thawed, filtered through 0.45 µm polycarbonate filters and diluted (1:50, v/v) with H<sub>2</sub>O.  
30 Diluted samples were chromatographed by HPLC using a Superdex Peptide PE (7.5 x 300 mm) gel filtration column (Global). The eluent used for isocratic elution was 50 mM sodium phosphate buffer (pH 7.0) containing 150 mM NaCl. The total volume of eluent per run was 26 ml and the flow rate was 0.4 ml/min. Elution profiles were recorded at 214 nm and the total area under the profiles was determined by integration. To estimate protein content from  
35 integrated areas, a calibration curve ( $R^2=0.9993$ ) was made from a dilution series of an *in vitro* digested reference maize/-SBM sample with known total protein content. The protein determination in this reference sample was carried out using the Kjeldahl method

(determination of % nitrogen; A.O.A.C. (1984) Official Methods of Analysis 14th ed., Washington DC).

The content of digested protein was estimated by integrating the chromatogram area corresponding to peptides and amino acids having a molecular mass of 1500 Dalton or below (Savoie, L.; Gauthier, S.F. Dialysis Cell For The In-vitro Measurement Of Protein Digestibility. J. Food Sci. 1986, 51, 494-498; Babinszky, L.; Van, D.M.J.M.; Boer, H.; Den, H.L.A. An In-vitro Method for Prediction of The Digestible Crude Protein Content in Pig Feeds. J. Sci. Food Agr. 1990, 50, 173-178; Boisen, S.; Eggum, B.O. Critical Evaluation of In-vitro Methods for Estimating Digestibility in Simple-Stomach Animals. Nutrition Research Reviews 1991, 4, 141-162). To determine the 1500 Dalton dividing line, the gel filtration column was calibrated using cytochrome C (Boehringer, Germany), aprotinin, gastrin I, and substance P (Sigma Aldrich, USA), as molecular mass standards.

### Results

The results shown in Tables 4 and 5 below indicate that the protease increased the Degree of Hydrolysis (DH), as well as soluble and digestible protein significantly.

**Table 4**

Degree of Hydrolysis (DH), absolute and relative values

Enzyme (dosage in mg EP/kg feed)	n	Of total protein			Relative to blank		
		%DH		SD	%DH		%CV
Blank	5	26.84	<sup>a</sup>	0.69	100.0	<sup>a</sup>	2.57
Protease of the invention (100)	5	28.21	<sup>b</sup>	0.35	105.1	<sup>b</sup>	1.25

20 Different letters within the same column indicate significant differences (1-way ANOVA, Tukey-Kramer test,  $P < 0.05$ ). SD = Standard Deviation. %CV = Coefficient of Variance = (SD/mean value) x 100%

**Table 5**

Solubilised and digested crude protein measured by ÄKTA HPLC.

Enzyme (dosage in mg EP/kg feed)	n	Of total protein				Relative to blank					
		%dig. CP	SD	%sol.CP	SD	%dig.CP	CV%	%sol.CP	CV%		
Blank	5	54.1 <sup>a</sup>	1.1	90.1 <sup>a</sup>	1.1	100.0 <sup>a</sup>	2.0	100.0 <sup>a</sup>	1.2		
Protease of the invention (50)	5	57.7 <sup>b</sup>	1.1	93.2 <sup>b</sup>	1.4	106.7 <sup>b</sup>	1.9	103.4 <sup>b</sup>	1.5		
(100)	5	58.9 <sup>b</sup>	0.8	94.8 <sup>b</sup>	0.9	108.9 <sup>b</sup>	1.3	105.2 <sup>b</sup>	0.9		

25 Different letters within the same column indicate significant differences (1-way ANOVA, Tukey-Kramer test,  $P < 0.05$ ). SD = Standard Deviation. %CV = Coefficient of Variance = (SD/mean value) x 100%

**EXAMPLE 4: Performance of the protease from *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235 in an aquaculture *in vitro* model**

The protease preparation as described in Example 3 was tested in an aquaculture *in vitro* model simulating the digestion in coldwater fish. The *in vitro* system consisted of 15  
5 flasks in which SBM substrate was initially incubated with HCl/pepsin – simulating gastric digestion - and subsequently with pancreatin – simulating intestinal digestion. 10 of the flasks were dosed with the protease at the start of the gastric phase whereas the remaining 5 flasks served as blanks. At the end of the intestinal incubation phase samples of *in vitro* digesta were removed and analysed for solubilised and digested protein.

Outline of aqua *in vitro* digestion procedure

Components added	pH	Temperature	Time course	Simulated digestion phase
10 g extruded SBM substrate, 62 mL HCl (0.155M)/pepsin (4000 U/g substrate), 1 mL of the protease of the invention	3.0	15°C	t=0 min	Gastric digestion
7 mL NaOH (1.1M)	6.8	15°C	t=6 hours	Intestinal digestion
5 mL NaHCO <sub>3</sub> (1M) / pancreatin (8 mg /g diet)	6.8	15°C	t=7 hours	Intestinal digestion
Terminate incubation	7.0	15°C	t=24 hours	

Conditions

Substrate: 10 g extruded SBM  
15 pH: 3.0 stomach step/ 6.8-7.0 intestinal step  
HCl: 0.155 M for 6 hours  
Pepsin: 4000 U /g diet for 6 hours  
Pancreatin: 8 mg/g diet for 17 hours  
Temperature: 15°C  
20 Replicates: 5

Solutions

1.1 M NaOH  
0.155 M HCl / pepsin (4000 U/g diet)  
25 1 M NaHCO<sub>3</sub> containing 16 mg pancreatin/mL  
125 mM NaAc-buffer, pH 6.0

Experimental procedure for aqua *in vitro* model

The experimental produce was according to the above outline. pH was measured at  
30 time 1, 5, 8 and 23 hours. Incubations were terminated after 24 hours and samples of 30 mL were removed and placed on ice before centrifugation (13000 x g, 10 min, 0°C). Supernatants were removed and stored at -20°C.

Analysis

All supernatants were analysed using the OPA method (% degree of hydrolysis) and by ÄKTA HPLC to determine solubilised and digested protein (see monogastric example).

5 Pre-treatment of *in vitro* supernatants with EASY SPE columns

Before analysis on ÄKTA HPLC supernatants from the *in vitro* system were pretreated using solid-phase sample purification. This was done to improve the chromatography and thereby prevent unstable elution profiles and baselines. The columns used for extraction were solid phase extraction columns (Chromabond EASY SPE Columns from Macherey-Nagel). 2 mL milliQ water was eluted through the columns by use of a vacuum chamber (vacuum 0.15 x 100 kPa). Subsequently 3 mL *in vitro* sample was dispensed onto the column and eluted (vacuum 0.1 x 100 kPa), the first ½ mL of eluted sample was thrown away and a clean tube was placed beneath the column, then the rest of the sample was eluted and saved for further dilution.

15

Results

The results shown in Tables 6 and 7 below indicate that the protease significantly increased Degree of hydrolysis and protein digestibility.

20 Table 6: Degree of Hydrolysis (DH)

Enzyme (mg EP/kg diet)	n	Of total protein			Relative to blank		
		%DH		SD	%DH		%CV
Blank	5	21.30	<sup>a</sup>	0.52	100.0	<sup>a</sup>	2.42
Protease of the invention (50)	5	21.98	<sup>b</sup>	0.22	103.2	<sup>b</sup>	1.00

Different letters within the same column indicate significant differences (1-way ANOVA, Tukey-Kramer test, P<0.05). SD = Standard Deviation. %CV = Coefficient of Variance = (SD/mean value) x 100%

Table 7: Solubilised and digested crude protein

Enzyme (mg EP/kg diet)	n	Of total protein						Relative to blank					
		%CP dig		SD	%CP sol		SD	%CP dig		% CV	%CP sol		CV %
Blank	5	50.0	<sup>a</sup>	2.2	89.9	<sup>a</sup>	3.2	100.0	<sup>a</sup>	4.5	100.0	<sup>a</sup>	3.5
Protease of the invention (50)	5	52.3	<sup>b</sup>	1.1	91.4	<sup>a</sup>	1.5	104.8	<sup>b</sup>	2.1	101.7	<sup>a</sup>	1.6
(100)	5	53.4	<sup>b</sup>	0.4	91.6	<sup>a</sup>	1.0	107.0	<sup>b</sup>	0.7	101.9	<sup>a</sup>	1.1

25 Different letters within the same column indicate significant differences (1-way ANOVA, Tukey-Kramer test, P<0.05). SD = Standard Deviation. %CV = Coefficient of Variance = (SD/mean value) x 100%.

**EXAMPLE 5: Construction of *Bacillus subtilis* strains L2, L2 HV0 and L2 HV1**

Two "Tail" variants (having C-terminal extensions) of the protease having the amino acid sequence of amino acids 1-188 of SEQ ID NO: 2 were also made. The tail variant



designated hereinafter L2 HV0 had the following 8 amino acids extra in the C-terminus: QSHVQSAP with the following DNA sequence extension inserted in front of the TAA stopcodon (between nucleotides 1059 and 1060 of SEQ ID NO: 1):

5'-CAATCGCATGTTCAATCCGCTCCA-3' (SEQ ID NO: 5)

The tail variant designated L2 HV1 had the following 4 amino acids extra in the C-terminus: QSAP, with the following DNA sequence extension inserted in front of the TAA stopcodon (between nucleotides 1059 and 1060 of SEQ ID NO: 1):

5'-CAATCGGCTCCT-3' (SEQ ID NO: 6)

Three strains of *Bacillus subtilis* were constructed: One harbouring the DNA construct encoding the protease having the amino acid sequence of amino acids 1-188 of SEQ ID NO: 2, denoted L2, and two harbouring the DNA constructs encoding the tail variants L2 HV0, and L2 HV1, respectively. These constructs were fused by PCR to the DNA coding for the signal peptide from SAVINASE™ *Bacillus clausii* (Takami,H.; Kobayashi,T.; Kobayashi,M.; Yamamoto,M.; Nakamura,S.; Aono,R.; Horikoshi,K.; Molecular cloning, nucleotide sequence and expression of the structural gene for alkaline protease from alkaliphilic *Bacillus* sp. 221) Biosci. Biotechnol. Biochem. 56:1455 (1992) and integrated by homologous recombination on the *Bacillus subtilis* host cell genome (described in Example 1). The genes are expressed under the control of a triple promoter system (as described in WO 99/43835), consisting of the promoters from *Bacillus licheniformis* alpha-amylase gene (amyL), *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ), and the *Bacillus thuringiensis* cryIIIA promoter including stabilizing sequence. The gene coding for Chloramphenicol acetyltransferase was used as marker. (Described in eg. Diderichsen,B.; Poulsen,G.B.; Joergensen,S.T.; A useful cloning vector for *Bacillus subtilis*. Plasmid 30:312 (1993)).

Chloramphenicol resistance transformants were checked for protease activity on 1% skim milk LB-PG agar plates (supplemented with 6 µg/ml chloramphenicol). Some protease positive colonies were further analyzed by DNA sequencing of the insert for correct gene DNA sequence and a strain of each construct was selected, called strain *B.subtilis* L2, *B.subtilis* L2 HV0, *B.subtilis* L2 HV1.

#### **EXAMPLE 6: Fermentation of the *B. subtilis* strains L2, L2 HV0 and L2 HV1**

The three *B. subtilis* strains L2, L2 HV0 and L2 HV1, were fermented on a rotary shaking table in 500 ml baffled Erlenmeyer flasks containing 100 ml TY supplemented with 6 mg/l chloramphenicol.

Six Erlenmeyer flasks for each of the three *B. subtilis* strains were fermented in parallel. Two of the six Erlenmeyer flasks were incubated at 37°C (250 rpm), two at 30°C (250 rpm), and the last two at 26°C (250 rpm).

A sample was taken from each shake flask at day 1, 2 and 3 and analyzed for proteolytic activity.

Table 8. Proteolytic activity at 37°C

Strain	Relative values at 37°C		
	Day 1	Day 2	Day 3
L2	1.0	1.0	1.0
L2-HV1	1.4	1.3	1.2
L2-HV0	1.3	1.1	1.4

5 Table 9. Proteolytic activity at 30°C

Strain	Relative values at 30°C		
	Day 1	Day 2	Day 3
L2	1.0	1.0	1.0
L2-HV1	1.0	1.2	1.4
L2-HV0	1.1	1.3	1.3

Table 10. Proteolytic activity at 26°C

Strain	Relative values at 26°C		
	Day 1	Day 2	Day 3
L2	1.0	1.0	1.0
L2-HV1	1.3	1.1	1.1
L2-HV0	0.2	1.1	1.1

As it can be seen from table 8-10 above the effect of the tails increases the expression level for the S2A protease from *Nocardioopsis dassonvillei* subsp. *dassonvillei*, DSM 43235 when expressed in *B. subtilis*. An increase of up to 40% is observed in this experiment, but overall an improvement is observed for both tail variants, L2 HV1 and L2 HV0, at all three temperatures tested.

## 15 EXAMPLE 7: Protease 22

A protease designated "Protease 22" was designed so as to comprise the following characteristic amino acids of the mature part (amino acids 1-188) of SEQ ID NO: 2: 10Y, 38T, 82S, 95P, 99A, 100V, 114I, 118N, 120T, 122R, 125Q, 129Y, 130S, 131L, 165S, and 171Y; wherein each position corresponds to a position of SEQ ID NO: 2.

20 The mature part of Protease 22 is amino acids 1-196 of SEQ ID NO: 8. The DNA sequence corresponding to SEQ ID NO: 8 is SEQ ID NO: 7.

The DNA sequence of SEQ ID NO: 7 was constructed and introduced into a *Bacillus* host for expression. The expressed protease was purified and characterized as an alpha-lytic protease (peptidase family S1E and/or S2A).

The temperature-activity relationship of Protease 22 was measured at pH9, using the Protazyme AK assay of Example 2. For comparison purposes the protease from *Nocardiopsis sp.* NRRL 18262 was included. The results are shown in Table 11 below.

The denaturation or melting temperature of Protease 22 was determined as  
5 described in Example 2 to  $T_m = 83.5^\circ\text{C}$ .

Table 11. Temperature profiles

Temperature ( $^\circ\text{C}$ )	Relative activity at pH 9	
	Protease 22	Protease from <i>Nocardiopsis sp.</i> NRRL 18262
15	0.016	0.015
25	0.010	0.024
37	0.028	0.068
50	0.069	0.199
60	0.138	0.510
70	0.474	1.000
80	1.000	0.394
90	0.375	-

From these results it appears that Protease 22 has a higher melting temperature, and  
10 a higher temperature optimum at pH 9, both as compared to the *Nocardiopsis sp.* NRRL 18262 protease, viz. a melting temperature increase of  $7.0^\circ\text{C}$ , and a temperature optimum increase of around  $10^\circ\text{C}$ .

#### EXAMPLE 8: Protease L2a

15 The mature part of protease L2a is amino acids 1-189 of SEQ ID NO: 10. SEQ ID NO: 9 is the DNA sequence corresponding to SEQ ID NO: 10.

The DNA sequence of SEQ ID NO: 9 was constructed and introduced into a *Bacillus* host for expression as described in Example 1, and purified as described in Example 2.

Protease L2a is an alpha-lytic protease (peptidase family S1E and/or S2A).

20 The temperature-activity relationship of protease L2a was measured at pH9, using the Protazyme AK assay of Example 2. For comparison purposes the protease from *Nocardiopsis sp.* NRRL 18262 (Protease 10) was included. The results are shown in Table 12 below.

The denaturation or melting temperature of the L2a protease was determined as  
25 described in Example 2 to  $T_m = 78.2^\circ\text{C}$ .

Table 12: Temperature activity profile

Temperature (°C)	L2a protease	Protease 10
15	0.02	0.02
25	0.02	0.02
37	0.05	0.07
50	0.13	0.20
60	0.31	0.51
70	0.79	1.00
80	1.00	0.39
90	0.28	-

From these results it appears that protease L2a has a higher melting temperature, and a higher temperature optimum at pH 9, both as compared to the *Nocardiosis* sp. NRRL 18262 protease, viz. a melting temperature increase of 1.7°C, and a temperature optimum increase of around 10°C.

#### EXAMPLE 9: Protease 8

The mature part of protease 8 is amino acids 1-188 of SEQ ID NO: 12. SEQ ID NO: 11 is the DNA sequence corresponding to SEQ ID NO: 12.

The DNA sequence of SEQ ID NO: 11 was constructed and introduced into a *Bacillus* host for expression as described in Example 1, and purified as described in Example 2.

Protease 8 is an alpha-lytic protease (peptidase family S1E and/or S2A).

The temperature-activity relationship of Protease 8 was measured at pH9, using the Protazyme AK assay of Example 2. For comparison purposes the protease from *Nocardiosis* sp. NRRL 18262 (Protease 10) was included. The results are shown in Table 13 below.

The denaturation or melting temperature of Protease 8 was determined as described in Example 2 to  $T_m = 78.3^\circ\text{C}$ .

Table 13: Temperature activity profile

Temperature (°C)	Protease 8	Protease 10
15	0.02	0.02
25	0.05	0.02
37	0.10	0.07
50	0.27	0.20
60	0.56	0.51
70	1.00	1.00
80	0.49	0.39
90	-	-

From these results it appears that Protease 8 has a higher melting temperature, and a higher temperature optimum at pH 9, both as compared to Protease 10, e.g. a melting temperature increase of 1.8°C.

#### EXAMPLE 10: Performance of the L2a Protease in a Monogastric In Vitro Digestion Model

The performance of the purified L2a protease described in Example 8 was tested in an *in vitro* model simulating the digestion in monogastric animals, in comparison with the known protease derived from *Nocardiosis* sp. NRRL 18262 ("Protease 10"). In particular, the protease was tested for its ability to improve solubilisation and digestion of maize/-SBM (maize/-soybean meal) proteins. The *in vitro* system consisted of 18 flasks in which maize/-SBM substrate was initially incubated with HCl/pepsin - simulating gastric digestion - and subsequently with pancreatin - simulating intestinal digestion. Eight of the flasks were dosed with the protease at the start of the gastric phase whereas the remaining ten flasks served as blanks. At the end of the intestinal incubation phase samples of *in vitro* digesta were removed and analysed for solubilised and digested protein.

Outline of in vitro digestion procedure

Components added	pH	Temperature	Time course	Simulated digestion phase
10 g maize/-SBM substrate (6:4), 41 ml HCl (0.105M)	3.0	40°C	t=0 min	Mixing
5 ml HCl (0.105M) / pepsin (3000 U/g substrate), 1 ml protease (to provide 100 mg protease enzyme protein per kg of substrate)	3.0	40°C	t=30 min	Gastric digestion
16 ml H <sub>2</sub> O	3.0	40°C	t= 1.0 hour	Gastric digestion
7 ml NaOH (0.39M)	6.8	40°C	t=1.5 hours	Intestinal digestion
5 ml NaHCO <sub>3</sub> (1M) / pancreatin (8 mg/g diet)	6.8	40°C	t=2.0 hours	Intestinal digestion
Terminate incubation	7.0	40°C	t=6.0 hours	

Conditions

- Substrate: 4 g SBM, 6 g maize (premixed)  
 5 pH: 3.0 stomach step/ 6.8-7.0 intestinal step  
 HCl: 0.105 M for 1.5 hours (i.e. 30 min HCl-substrate premixing)  
 pepsin: 3000 U /g diet for 1 hour  
 pancreatin: 8 mg/g diet for 4 hours  
 temperature: 40°C,  
 10 Replicates: n

Solutions

- 0.39 M NaOH  
 0.105 M HCl  
 15 0.105 M HCl containing 6000 U pepsin per 5 ml  
 1 M NaHCO<sub>3</sub> containing 16 mg pancreatin per ml  
 125 mM NaAc-buffer, pH 6.0

Enzyme protein determinations

- 20 The amount of protease enzyme protein (EP) is calculated on the basis of the  $A_{280}$  values and the amino acid sequences (amino acid compositions) using the principles outlined in S.C.Gill & P.H. von Hippel, Analytical Biochemistry 182, 319-326, (1989).

Experimental procedure for in vitro model

- 25 The experimental procedure was according to the above outline. pH was measured at time 1, 2.5, and 5.5 hours. Incubations were terminated after 6 hours and samples of 30 ml were removed and placed on ice before centrifugation (10000 x g, 10 min, 4°C). Supernatants were removed and stored at 20°C.

30 Analysis

All samples were analysed for content of solubilised and digested protein using gel filtration.

### Estimation of solubilised and digested protein

The content of solubilised protein in supernatants from in vitro digested samples was estimated by quantifying crude protein (CP) using gel filtration HPLC. Supernatants were thawed, filtered through 0.45 µm polycarbonate filters and diluted (1:50, v/v) with H<sub>2</sub>O. Diluted samples were chromatographed by HPLC using a Superdex Peptide PE (7.5 x 300 mm) gel filtration column (Global). The eluent used for isocratic elution was 50 mM sodium phosphate buffer (pH 7.0) containing 150 mM NaCl. The total volume of eluent per run was 26 ml and the flow rate was 0.4 ml/min. Elution profiles were recorded at 214 nm and the total area under the profiles was determined by integration. To estimate protein content from integrated areas, a calibration curve ( $R^2=0.9993$ ) was made from a dilution series of an in vitro digested reference maize/SBM sample with known total protein content. The protein determination in this reference sample was carried out using the Kjeldahl method (determination of % nitrogen; A.O.A.C. (1984) Official Methods of Analysis 14th ed., Washington DC).

The content of digested protein was estimated by integrating the chromatogram area corresponding to peptides and amino acids having a molecular mass of 1500 Dalton or below (Savoie, L.; Gauthier, S.F. Dialysis Cell For The In-vitro Measurement Of Protein Digestibility. J. Food Sci. 1986, 51, 494-498; Babinszky, L.; Van, D.M.J.M.; Boer, H.; Den, H.L.A. An In-vitro Method for Prediction of The Digestible Crude Protein Content in Pig Feeds. J. Sci. Food Agr. 1990, 50, 173-178; Boisen, S.; Eggum, B.O. Critical Evaluation of In-vitro Methods for Estimating Digestibility in Simple-Stomach Animals. Nutrition Research Reviews 1991, 4, 141-162). To determine the 1500 Dalton dividing line, the gel filtration column was calibrated using cytochrome C (Boehringer, Germany), aprotinin, gastrin I, and substance P (Sigma Aldrich, USA), as molecular mass standards.

### Results

The results shown in Table 14 below indicate that the L2a protease, like Protease 10, significantly increased the level of soluble and digestible protein relative to the blank. Furthermore, the L2a protease appears to at least numerically improve the level of digestible protein as compared to the known Protease 10.



Table 14: Solubilised and digested crude protein

Enzyme	n	Relative to blank					
		%digestible CP		CV%	%soluble CP		CV%
Blank	10	100.0	<sup>a</sup>	5.5	100.0	<sup>a</sup>	4.4
L2a protease	3	116.1	<sup>b</sup>	0.7	107.2	<sup>b</sup>	1.1
Protease 10	5	112.1	<sup>b</sup>	1.0	110.2	<sup>b</sup>	0.6

Different letters within the same column indicate significant differences (1-way ANOVA, Tukey-Kramer test,  $P < 0.05$ ). SD = Standard Deviation. %CV = Coefficient of Variance = (SD/mean value) x 100%

## 5 EXAMPLE 11: Fish Feeding Trial

Rainbow trout (*Oncorhynchus mykiss*), all female stock with an initial body weight of approximately 27.3 g, were fed a practical basal diet containing 49% SBM (Soy Bean Meal) and 12% FM (Fish Meal), without (Control), and with, addition of the protease of the invention having amino acids 1-188 of SEQ ID NO: 2, in an amount of 50 mg protease enzyme protein / kg feed. Fish were fed ad libitum. The feeding trial was performed in 500 l tanks, part of a semi-recirculating unit with a water temperature of 15°C +/- 1°C, with 50 fish per tank and 4 replicates per treatment. Survival, growth, and feed conversion were measured over an 85-days feeding period.

The results are shown in Table 15 below. A significant increase in bodyweight was obtained by addition of the protease of the invention to the diet.

Table 15: *In vivo* fish results

Treatment	Survival %	Initial Body Weight / g	Final Body Weight / g	Weight Gain / g
Control	100.0 +/- 0.0	27.3 +/- 0.0	305.0 +/- 5.3	277.7 +/- 5.3
Protease 1-188 of SEQ ID NO: 2	100.0 +/- 0.0	27.3 +/- 0.0	333.5 +/- 4.7	306.2 +/- 4.7

## EXAMPLE 12: Proteolytic Degradation of Major Purified Soybean Proteins

We have studied the ability of the protease from *Nocardopsis* sp. NRRL 18262 and the protease of the invention having amino acids 1-188 of SEQ ID NO: 2 to degrade purified soy proteins. The purified soy proteins studied were three so-called anti-nutritional factors of soy protein: Soybean agglutinin (SBA), the soybean Kunitz trypsin inhibitor, the soybean Bowman-Birk inhibitor; and two of the major storage proteins from soy: Glycinin and beta-conglycinin.

These soy proteins were obtained as follows: SBA was purified from unheated soybean meal (prod. No. S-9633, Sigma) by affinity chromatography using N-aminocaproyl-

beta-D-galactopyranosylamine Sepharose (Sigma) Fractions eluting from the column were analysed using SDS-PAGE (Tris-glycine 4-20%), and fractions containing essentially pure protein were pooled. Soybean glycinin and beta-conglycinin were purified according to the procedures described by Fischer, M. et al: Enzymatic Extractability of Soybean Meal Proteins and Carbohydrates: Heat and Humidity Effects. J.Agric.Food Chem. 2001, 49, 4463-4469. The Bowman-Birk inhibitor and the Kunitz trypsin inhibitor are commercial products (Sigma T-9777 and Fluka 93618, respectively).

The purified soy proteins were incubated with the two proteases for 4 hours at 37°C and pH 6.5 (protease: soy protein = 1:10, based on A<sub>280</sub>). Incubation buffer: 50 mM dimethyl glutaric acid, 150 mM NaCl, 1 mM CaCl<sub>2</sub>, 0.01% Triton X-100, pH 6.5.

The ability of the proteases to degrade each of these five proteins was estimated as the relative intensity decrease of the intact soy protein band on SDS-PAGE (Tris-glycine 4-20%) gels stained with Coomassie Brilliant Blue. In case of glycinin and beta-conglycinin, the term "the intact soy protein band" in fact refers to two and three bands, respectively, as these two proteins, when subjected to the reducing environment on the SDS-PAGE gel, denature under the formation of two and three sub-units, respectively.

The intensity of the intact soy protein bands (before and after treatment with the two proteases) was determined by scanning the stained SDS gels, and the degradation of each of the five proteins by each of the two proteases determined as the intensity of the respective intact soy protein band after, relative to the intensity of the respective intact soy protein band before the protease treatment. The percentage protein degradation is calculated as follows: 100% - ((band intensity after/ band intensity before) x 100%). The results are shown in Table 16 below.

Table 16. Percentage degradation of isolated soy proteins

Protease	SBA	Bowman-Birk Inhibitor	Kunitz trypsin Inhibitor	Glycinin	Beta-conglycinin
From <i>Nocardopsis</i> sp. NRRL 18262	100	35	94	98	95
Protease having amino acids 1-188 of SEQ ID NO: 2	95	81	97	100	100

#### EXAMPLE 13: Animal Feed and Animal Feed Additives

An animal feed additive comprising the protease of the invention having amino acids 1-188 of SEQ ID NO: 2, in the form of a vitamins and mineral premix, is composed as shown in Table 17 below. The vitamins and the carotenoids are commercially available from DSM Nutritional Products. All amounts are in g/kg.

Table 17: Premix composition

Vitamin A	ROVIMIX A 500	4.00
Vitamin D3	ROVIMIX D3 500	1.00
Vitamin E	ROVIMIX E 50 Ads	8.00
Vitamin B2	ROVIMIX B2 80-SD	1.0
	CAROPHYLL Yellow	10.0
	Choline chloride 50%, min.	300.0
Minerals	Mn Oxide	60.0
	Zn Oxide	12.0
	Fe Sulphate monohydrate	20.0
	Cu Oxide	2.0
	Co Sulphate	0.2
Enzyme	Protease having amino acids 1-188 of SEQ ID NO: 2 (enzyme protein)	3.0
	Wheat middlings	578.8

- The Premix of Table 17 is included in a trout feed with a composition as shown in Table 18 below. The amount of each ingredient is indicated in % (w/w). The in-feed-concentration of the protease of the invention is 51 mg protease enzyme protein per kg.

Table 18: Trout feed composition

Wheat	11.20
Soya	14.00
Fish meal	57.00
Soya oil	4.00
Starch	8.00
Yeast	4.00
Choline chloride 75%	0.10
Premix of Table 17	1.70

PCT

Original (for SUBMISSION)

(This sheet is not part of and does not count as a sheet of the international application)

0-1	Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared Using	PCT-SAFE [EASY model] Version 3.50 (Build 0002.162)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	10436.504-WO

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	52
1-2	line	18
1-3	Identification of deposit	
1-3-1	Name of depositary institution	DSMZ DSMZ-Deutsche Sammlung von Mikroor- ganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	30 May 2003 (30.05.2003)
1-3-4	Accession Number	DSMZ 15647
1-4	Additional Indications	Nocardiosis alba
1-5	Designated States for Which Indications are Made	all designations
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	52
2-2	line	19
2-3	Identification of deposit	
2-3-1	Name of depositary institution	DSMZ DSMZ-Deutsche Sammlung von Mikroor- ganismen und Zellkulturen GmbH
2-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
2-3-3	Date of deposit	24 May 2004 (24.05.2004)
2-3-4	Accession Number	DSMZ 16424
2-4	Additional Indications	Nocardiosis sp.
2-5	Designated States for Which Indications are Made	all designations

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	Yes
0-4-1	Authorized officer	Dr. G. Warr. alad

PCT

Original (for SUBMISSION)

(This sheet is not part of and does not count as a sheet of the international application)

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	09 JUL 2004 (09.07.2004)
0-5-1	Authorized officer	J. Svàrez PTO9

Our ref: 10436.504-WO

**Additional Indications (Form PCT/RO/134)**

**Statement regarding the "expert option"**


Deposited microorganisms:

With respect to the deposited microorganism set out on Form PCT/RO/134 we request the so-called expert option:

Until the publication of the mention of grant of a European patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed withdrawn, a sample of the deposited micro-organism is only to be provided to an independent expert nominated by the person requesting the sample (cf. Rule 28(4) EPC). And as far as Australia is concerned, the expert option is likewise requested, reference being had to Regulation 3.25 of Australia Statutory Rules 1991 No 71. Also, for Canada we request that only an independent expert nominated by the Commissioner is authorized to have access to a sample of the microorganism deposited.

Bagsværd, 21 June 2004

Novozymes A/S

  
.....

Karen Østergaard Pedersen, Patent Counsel

## CLAIMS

1. An isolated polypeptide having protease activity, and having a melting temperature ( $T_m$ ) of at least 78°C, as determined by Differential Scanning Calorimetry (DSC) in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0, using a constant scan rate of 1.5°C/min, wherein the polypeptide is selected from the group consisting of:
- 5 (a) a polypeptide having an amino acid sequence which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12 of at least 60%;
- 10 (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under low stringency conditions with either of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11; and
- (c) a polypeptide which is encoded by a nucleic acid sequence which has a degree of identity to any one of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%.
- 15 2. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of claim 1.
- 20 3. An isolated nucleic acid sequence comprising a nucleic acid sequence which encodes a polypeptide having protease activity and a melting temperature ( $T_m$ ) of at least 78°C, as determined by Differential Scanning Calorimetry (DSC) in a 10 mM sodium phosphate, 50 mM sodium chloride buffer, pH 7.0, using a constant scan rate of 1.5 °C/min, wherein the nucleic acid sequence
- 25 (a) hybridizes under low stringency conditions with any one of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11;
- (b) has a degree of identity to any one of nucleotides 499-1062 of SEQ ID NO: 1, 577-1164 of SEQ ID NO: 7, 586-1152 of SEQ ID NO: 9, and/or 502-1065 of SEQ ID NO: 11 of at least 60%; and/or
- 30 (c) encodes a polypeptide which has a degree of identity to amino acids 1 to 188 of SEQ ID NO: 2, 1 to 196 of SEQ ID NO: 8, 1 to 189 of SEQ ID NO: 10, and/or 1 to 188 of SEQ ID NO: 12 of at least 60%.
- 35 4. A nucleic acid construct comprising the nucleic acid sequence of any one of claims 2-3 operably linked to one or more control sequences that direct the production of the polypeptide in a suitable expression host.



5. A recombinant expression vector comprising the nucleic acid construct of claim 4.
6. A recombinant host cell comprising the nucleic acid construct of claim 4 or the vector  
5 of claim 5.
7. A method for producing a polypeptide of claim 1, the method comprising: (a) cultivating a recombinant host cell of claim 6 to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.  
10
8. A transgenic plant, or plant part, capable of expressing the polypeptide of claim 1.
9. A transgenic, non-human animal, or products, or elements thereof, being capable of expressing the polypeptide of claim 1.  
15
10. A method for producing a polypeptide of claim 1, the method comprising  
(a) cultivating any one of the following strains:  
(i) *Nocardiopsis dassonvillei* subsp. *dassonvillei* DSM 43235,  
(ii) *Nocardiopsis* sp. DSM 16424, or  
20 (iii) *Nocardiopsis alba* DSM 15647; and  
(b) recovering the polypeptide.
11. Use of at least one polypeptide as defined in claim 1 (i) in animal feed; (ii) in the preparation of a composition for use in animal feed; (iii) for improving the nutritional value of  
25 an animal feed; (iv) for increasing digestible and/or soluble protein in animal diets; (v) for increasing the degree of hydrolysis of proteins in animal diets; and/or (vi) for the treatment of proteins.
12. An animal feed additive comprising at least one polypeptide as defined in claim 1;  
30 and  
(a) at least one fat-soluble vitamin, and/or  
(b) at least one water-soluble vitamin, and/or  
(c) at least one trace mineral.
- 35 13. An animal feed composition having a crude protein content of 50 to 800 g/kg and comprising at least one polypeptide as defined in claim 1, or at least one feed additive of claim 12.

14. The feed composition of claim 13 which is a fish feed.
15. A composition comprising at least one polypeptide as defined in claim 1, together with  
5 at least one other enzyme selected from amongst amylase, phytase, xylanase, galactanase, alpha-galactosidase, protease, phospholipase, and/or beta-glucanase.
16. Use of at least one polypeptide as defined in claim 1 in detergents.
- 10 17. *Nocardiopsis* sp. DSM 16424.
18. *Nocardiopsis alba* DSM 15647.

10436.504-WO.ST25  
SEQUENCE LISTING

&lt;110&gt; Novozymes A/S

&lt;120&gt; Proteases

&lt;130&gt; 10436.504-WO

&lt;160&gt; 12

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 1065

&lt;212&gt; DNA

&lt;213&gt; Nocardiosis dassonvillei subsp. dassonvillei DSM 43235

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1062)

&lt;220&gt;

&lt;221&gt; mat\_peptide

&lt;222&gt; (499)..(1062)

&lt;400&gt; 1

gct ccg gcc ccc gtc ccc cag acc ccc gtc gcc gac gac agc gcc	45
Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala	
-165 -160 -155	

gcc agc atg acc gag gcg ctc aag cgc gac ctc gac ctc acc tcg	90
Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser	
-150 -145 -140	

gcc gag gcc gag gag ctt ctc tcg gcg cag gaa gcc gcc atc gag	135
Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu	
-135 -130 -125	

acc gac gcc gag gcc acc gag gcc gcg ggc gag gcc tac ggc ggc	180
Thr Asp Ala Glu Ala Thr Glu Ala Ala Gly Glu Ala Tyr Gly Gly	
-120 -115 -110	

tca ctg ttc gac acc gag acc ctc gaa ctc acc gtg ctg gtc acc gac	228
Ser Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp	
-105 -100 -95	

gcc tcc gcc gtc gag gcg gtc gag gcc acc gga gcc cag gcc acc gtc	276
Ala Ser Ala Val Glu Ala Val Glu Ala Thr Gly Ala Gln Ala Thr Val	
-90 -85 -80 -75	

gtc tcc cac ggc acc gag ggc ctg acc gag gtc gtg gag gac ctc aac	324
Val Ser His Gly Thr Glu Gly Leu Thr Glu Val Val Glu Asp Leu Asn	
-70 -65 -60	

ggc gcc gag gtt ccc gag agc gtc ctc ggc tgg tac ccg gac gtg gag	372
Gly Ala Glu Val Pro Glu Ser Val Leu Gly Trp Tyr Pro Asp Val Glu	
-55 -50 -45	

agc gac acc gtc gtg gtc gag gtg ctg gag ggc tcc gac gcc gac gtc	420
Ser Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val	
-40 -35 -30	

gcc gcc ctg ctc gcc gac gcc ggt gtg gac tcc tcc tcg gtc cgg gtg	468
Ala Ala Leu Leu Ala Asp Ala Gly Val Asp Ser Ser Ser Val Arg Val	
-25 -20 -15	

gag gag gcc gag gag gcc ccg cag gtc tac gcc gac atc atc ggc ggc	516
---	-----

10436.504-WO.ST25

Glu -10	Glu	Ala	Glu	Glu	Ala -5	Pro	Gln	Val	Tyr -1	Ala 1	Asp	Ile	Ile	Gly 5	Gly		
ctg	gcc	tac	tac	atg	ggc	ggc	ggc	tgc	tcc	gtc	ggc	ttc	gcc	gcg	acc		564
Leu	Ala	Tyr	Tyr	Met	Gly	Gly	Arg	Cys 15	Ser	Val	Gly	Phe	Ala 20	Ala	Thr		
			10														
aac	agc	gcc	ggt	cag	ccc	ggt	ttc	gtc	acc	gcc	ggc	cac	tgc	ggc	acc		612
Asn	Ser	Ala 25	Gly	Gln	Pro	Gly	Phe 30	Val	Thr	Ala	Gly	His 35	Cys	Gly	Thr		
gtc	ggc	acc	ggc	gtg	acc	atc	ggc	aac	ggc	acc	ggc	acc	ttc	cag	aac		660
Val	Gly 40	Thr	Gly	Val	Thr	Ile 45	Gly	Asn	Gly	Thr	Gly 50	Thr	Phe	Gln	Asn		
tcg	gtc	ttc	ccc	ggc	aac	gac	ggc	ggc	ttc	gtc	cgc	ggc	acc	tcc	aac		708
Ser	Val	Phe	Pro	Gly	Asn 60	Asp	Ala	Ala	Phe	Val 65	Arg	Gly	Thr	Ser	Asn 70		
ttc	acc	ctg	acc	aac	ctg	gtc	tcg	cgc	tac	aac	tcc	ggc	ggc	tac	cag		756
Phe	Thr	Leu	Thr	Asn 75	Leu	Val	Ser	Arg	Tyr 80	Asn	Ser	Gly	Gly	Tyr 85	Gln		
tcg	gtg	acc	ggt	acc	agc	cag	ggc	ccg	ggc	ggc	tcg	gcc	gtg	tgc	cgc		804
Ser	Val	Thr	Gly 90	Thr	Ser	Gln	Ala	Pro 95	Ala	Gly	Ser	Ala	Val 100	Cys	Arg		
tcc	ggc	tcc	acc	acc	ggc	tgg	cac	tgc	ggc	acc	atc	cag	gcc	cgc	aac		852
Ser	Gly	Ser 105	Thr	Thr	Gly	Trp	His 110	Cys	Gly	Thr	Ile	Gln 115	Ala	Arg	Asn		
cag	acc	gtg	cgc	tac	ccg	cag	ggc	acc	gtc	tac	tcg	ctc	acc	cgc	acc		900
Gln	Thr	Val	Arg	Tyr	Pro	Gln 125	Gly	Thr	Val	Tyr	Ser 130	Leu	Thr	Arg	Thr		
aac	gtg	tgc	ggc	gag	ccc	ggc	gac	tcc	ggc	ggt	tcg	ttc	atc	tcc	ggc		948
Asn	Val	Cys	Ala	Glu	Pro 140	Gly	Asp	Ser	Gly	Gly 145	Ser	Phe	Ile	Ser	Gly 150		
tcg	cag	ggc	cag	ggc	gtc	acc	tcc	ggc	ggc	tcc	ggc	aac	tgc	tcc	gtc		996
Ser	Gln	Ala	Gln 155	Gly	Val	Thr	Ser	Gly	Gly 160	Ser	Gly	Asn	Cys	Ser 165	Val		
ggc	ggc	acg	acc	tac	tac	cag	gag	gtc	acc	ccg	atg	atc	aac	tcc	tgg		1044
Gly	Gly	Thr	Thr 170	Tyr	Tyr	Gln	Glu	Val 175	Thr	Pro	Met	Ile	Asn 180	Ser	Trp		
ggt	gtc	agg	atc	cgg	acc	taa											1065
Gly	Val	Arg 185	Ile	Arg	Thr												

&lt;210&gt; 2

&lt;211&gt; 354

&lt;212&gt; PRT

&lt;213&gt; Nocardiopsis dassonvillei subsp. dassonvillei DSM 43235

&lt;400&gt; 2

Ala Pro Ala Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala  
-165 -160 -155

Ala Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asp Leu Thr Ser  
-150 -145 -140

Ala Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu

Page 3

<400> 6

10436.504-WO.ST25

caatcggctc ct

12

<210> 7  
 <211> 1164  
 <212> DNA  
 <213> Synthetic ("Protease 22")

<220>  
 <221> CDS  
 <222> (1)..(1164)

<220>  
 <221> sig\_peptide  
 <222> (1)..(81)

<220>  
 <221> misc\_feature  
 <222> (82)..(576)  
 <223> Propeptide

<220>  
 <221> mat\_peptide  
 <222> (577)..(1164)

<400> 7  
 atg aaa aaa ccg ctg gga aaa att gtc gca agc aca gca ctt ctt 45  
 Met Lys Lys Pro Leu Gly Lys Ile Val Ala Ser Thr Ala Leu Leu  
 -190 -185 -180

att tca gtg gca ttt agc tca tct att gca tca gca gct aca gga 90  
 Ile Ser Val Ala Phe Ser Ser Ser Ile Ala Ser Ala Ala Thr Gly  
 -175 -170 -165

gca tta ccg cag tct ccg aca ccg gaa gca gat gca gtc tca atg 135  
 Ala Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala Val Ser Met  
 -160 -155 -150

caa gaa gca ctg caa aga gat ctt gat ctt aca tca gca gaa gca 180  
 Gln Glu Ala Leu Gln Arg Asp Leu Asp Leu Thr Ser Ala Glu Ala  
 -145 -140 -135

gaa gaa ctt ctt gct gca caa gat aca gca ttt gaa gtg gat gaa 225  
 Glu Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu Val Asp Glu  
 -130 -125 -120

gca gcg gca gaa gca gca gga gat gca tat ggc ggc tca gtt ttt 270  
 Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly Ser Val Phe  
 -115 -110 -105

gat aca gaa tca ctt gaa ctt aca gtt ctt gtt aca gat gca gca gca 318  
 Asp Thr Glu Ser Leu Glu Leu Thr Val Leu Val Thr Asp Ala Ala Ala  
 -100 -95 -90

gtt gaa gca gtt gaa gca aca gga gca gga aca gta ctt gtt tca tat 366  
 Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Val Leu Val Ser Tyr  
 -85 -80 -75

gga att gat ggc ctt gat gaa att gtt caa gaa ctg aat gca gct gat 414  
 Gly Ile Asp Gly Leu Asp Glu Ile Val Gln Glu Leu Asn Ala Ala Asp  
 -70 -65 -60 -55

gct gtt ccg ggc gtt gtt ggc tgg tat ccg gat gtt gct gga gat aca 462  
 Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala Gly Asp Thr  
 -50 -45 -40

gtt gtc ctt gaa gtt ctt gaa gga tca ggc gca gat gtt tca ggc ctg 510



10436.504-WO.ST25

Val	Val	Leu	Glu	Val	Leu	Glu	Gly	Ser	Gly	Ala	Asp	Val	Ser	Gly	Leu		
		-35						-30				-25					
ctg	gca	gac	gca	gga	gtc	gat	gca	tca	gca	gtt	gaa	gtt	aca	aca	tca	558	
Leu	Ala	Asp	Ala	Gly	Val	Asp	Ala	Ser	Ala	Val	Glu	Val	Thr	Thr	Ser		
		-20					-15					-10					
gat	caa	ccg	gaa	ctt	tat	gca	gat	att	att	ggc	ggc	ctg	gca	tat	tat	606	
Asp	Gln	Pro	Glu	Leu	Tyr	Ala	Asp	Ile	Ile	Gly	Gly	Leu	Ala	Tyr	Tyr		
	-5				-1	1				5				10			
atg	ggc	ggc	aga	tgc	agc	gtt	ggc	ttt	gca	gca	aca	aat	gca	tca	ggc	654	
Met	Gly	Gly	Arg	Cys	Ser	Val	Gly	Phe	Ala	Ala	Thr	Asn	Ala	Ser	Gly		
				15					20					25			
caa	ccg	ggc	ttt	gtt	aca	gca	ggc	cat	tgc	ggc	aca	gtt	ggc	aca	cca	702	
Gln	Pro	Gly	Phe	Val	Thr	Ala	Gly	His	Cys	Gly	Thr	Val	Gly	Thr	Pro		
			30					35					40				
gtt	tca	att	ggc	aat	ggc	aaa	ggc	gtt	ttt	gaa	cga	agc	att	ttt	ccg	750	
Val	Ser	Ile	Gly	Asn	Gly	Lys	Gly	Val	Phe	Glu	Arg	Ser	Ile	Phe	Pro		
		45					50					55					
ggc	aat	gat	tca	gca	ttt	gtt	aga	ggc	aca	tca	aat	ttt	aca	ctt	aca	798	
Gly	Asn	Asp	Ser	Ala	Phe	Val	Arg	Gly	Thr	Ser	Asn	Phe	Thr	Leu	Thr		
	60					65				70							
aat	ctg	gtt	tca	aga	tat	aat	tca	ggc	ggc	tat	gca	aca	gtt	gca	ggc	846	
Asn	Leu	Val	Ser	Arg	Tyr	Asn	Ser	Gly	Gly	Tyr	Ala	Thr	Val	Ala	Gly		
	75				80					85					90		
cat	aat	caa	gca	ccg	att	ggc	tca	gca	gtt	tgc	aga	tca	ggc	tca	aca	894	
His	Asn	Gln	Ala	Pro	Ile	Gly	Ser	Ala	Val	Cys	Arg	Ser	Gly	Ser	Thr		
				95					100					105			
aca	ggc	tgg	cat	tgc	ggc	aca	att	caa	gca	aga	aat	caa	aca	gtt	agg	942	
Thr	Gly	Trp	His	Cys	Gly	Thr	Ile	Gln	Ala	Arg	Asn	Gln	Thr	Val	Arg		
			110					115					120				
tat	ccg	caa	ggc	aca	gtt	tat	agt	ctg	aca	aga	aca	aca	gtt	tgt	gca	990	
Tyr	Pro	Gln	Gly	Thr	Val	Tyr	Ser	Leu	Thr	Arg	Thr	Thr	Val	Cys	Ala		
		125					130						135				
gaa	ccg	ggc	gat	tca	ggc	ggc	tca	tat	att	agc	ggc	act	caa	gca	caa	1038	
Glu	Pro	Gly	Asp	Ser	Gly	Gly	Ser	Tyr	Ile	Ser	Gly	Thr	Gln	Ala	Gln		
	140					145					150						
ggc	gtt	aca	tca	ggc	ggc	tca	ggc	aat	tgc	agt	gct	ggc	ggc	aca	aca	1086	
Gly	Val	Thr	Ser	Gly	Gly	Ser	Gly	Asn	Cys	Ser	Ala	Gly	Gly	Thr	Thr		
	155				160				165						170		
tat	tac	caa	gaa	gtt	aat	ccg	atg	ctt	agt	tca	tgg	ggc	ctt	aca	ctt	1134	
Tyr	Tyr	Gln	Glu	Val	Asn	Pro	Met	Leu	Ser	Ser	Trp	Gly	Leu	Thr	Leu		
				175					180					185			
aga	aca	caa	tgc	cat	gtt	caa	tcc	gct	cca							1164	
Arg	Thr	Gln	Ser	His	Val	Gln	Ser	Ala	Pro								
			190					195									

<210> 8  
 <211> 388  
 <212> PRT  
 <213> Synthetic ("Protease 22")

<400> 8

Met Lys Lys Pro Leu Gly Lys Ile Val Ala Ser Thr Ala Leu Leu

10436.504-WO.ST25

-190 -185 -180

Ile Ser Val Ala Phe Ser Ser Ser Ile Ala Ser Ala Ala Thr Gly  
-175 -170 -165

Ala Leu Pro Gln Ser Pro Thr Pro Glu Ala Asp Ala Val Ser Met  
-160 -155 -150

Gln Glu Ala Leu Gln Arg Asp Leu Asp Leu Thr Ser Ala Glu Ala  
-145 -140 -135

Glu Glu Leu Leu Ala Ala Gln Asp Thr Ala Phe Glu Val Asp Glu  
-130 -125 -120

Ala Ala Ala Glu Ala Ala Gly Asp Ala Tyr Gly Gly Ser Val Phe  
-115 -110 -105

Asp Thr Glu Ser Leu Glu Leu Thr Val Leu Val Thr Asp Ala Ala Ala  
-100 -95 -90

Val Glu Ala Val Glu Ala Thr Gly Ala Gly Thr Val Leu Val Ser Tyr  
-85 -80 -75

Gly Ile Asp Gly Leu Asp Glu Ile Val Gln Glu Leu Asn Ala Ala Asp  
-70 -65 -60 -55

Ala Val Pro Gly Val Val Gly Trp Tyr Pro Asp Val Ala Gly Asp Thr  
-50 -45 -40

Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp Val Ser Gly Leu  
-35 -30 -25

Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Glu Val Thr Thr Ser  
-20 -15 -10

Asp Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly Gly Leu Ala Tyr Tyr  
-5 -1 1 5 10

Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn Ala Ser Gly  
15 20 25

Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr Val Gly Thr Pro  
30 35 40

Val Ser Ile Gly Asn Gly Lys Gly Val Phe Glu Arg Ser Ile Phe Pro  
45 50 55

Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser Asn Phe Thr Leu Thr  
60 65 70

Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly Tyr Ala Thr Val Ala Gly

10436.504-WO.ST25

75	80	85	90
His Asn Gln Ala	Pro Ile Gly Ser Ala	Val Cys Arg Ser Gly	Ser Thr
	95	100	105
Thr Gly Trp	His Cys Gly Thr Ile	Gln Ala Arg Asn Gln	Thr Val Arg
	110	115	120
Tyr Pro Gln Gly	Thr Val Tyr Ser	Leu Thr Arg Thr	Thr Val Cys Ala
	125	130	135
Glu Pro Gly Asp	Ser Gly Gly Ser Tyr	Ile Ser Gly Thr	Gln Ala Gln
	140	145	150
Gly Val Thr Ser	Gly Gly Ser Gly	Asn Cys Ser Ala	Gly Gly Thr Thr
	155	160	165
Tyr Tyr Gln Glu	Val Asn Pro Met	Leu Ser Ser Trp	Gly Leu Thr Leu
	175	180	185
Arg Thr Gln Ser	His Val Gln Ser	Ala Pro	
	190	195	

<210> 9  
 <211> 1155  
 <212> DNA  
 <213> Nocardiosis sp. DSM 16424

<220>  
 <221> sig\_peptide  
 <222> (1)..(87)  
 <220>  
 <221> CDS  
 <222> (1)..(1152)  
 <220>  
 <221> mat\_peptide  
 <222> (586)..(1152)

<400> 9		
atg aga ccc tcc acc atc gcc tcc gcc gtc ggc aca gga gca ctg		45
Met Arg Pro Ser Thr Ile Ala Ser Ala Val Gly Thr Gly Ala Leu		
-195 -190 -185		
gcc ttc ggt ctg gca ctg tcc atg gcc ccc gga gcc ctc gcg gcg		90
Ala Phe Gly Leu Ala Leu Ser Met Ala Pro Gly Ala Leu Ala Ala		
-180 -175 -170		
ccc ggc ccc gtc ccc cag acc ccc gtc gcc gac gac agc gcc gcc		135
Pro Gly Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala Ala		
-165 -160 -155		
agc atg acc gaa gcg ctc aag cgt gac ctc aac ctc tcc tcg gcc		180
Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asn Leu Ser Ser Ala		
-150 -145 -140		
gag gcc gag gag ctg ctc tcg gcg cag gaa gcc gcg atc gag acc		225
Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu Thr		

10436.504-WO.ST25																	
-135						-130						-125					
gac Asp -120	gcc Ala	gag Glu	gcc Ala	gcc Ala	gag Glu	gcc Ala	gag Ala	gga Gly	gag Glu	gcc Ala	tac Tyr	ggc Gly	ggc Gly	tcc Ser	270		
ctg Leu -105	ttc Phe	gac Asp	acc Thr	gaa Glu	acc Thr	ctc Leu	gaa Glu	ctc Leu	acc Thr	gtg Val	ctg Leu	gtg Val	acc Thr	gac Asp	acc Thr	318	
acg Thr	gcc Ala	gtc Val	gac Asp	gag Ala	gtc Val	gag Glu	gcc Ala	acc Thr	gga Gly	gcc Ala	gag Glu	gcc Ala	acc Thr	gtg Val	gtc Val	366	
acc Thr	cac His	ggc Gly	acc Thr	gac Asp	ggc Gly	ctg Leu	gcc Ala	gag Glu	gtc Val	gtg Val	gag Glu	gac Asp	ctc Leu	aac Asn	agc Ser	414	
gcc Ala	gac Asp	gcc Ala	ccg Pro	gag Ala	ggc Gly	gtc Val	ctc Leu	ggc Gly	tgg Trp	tac Tyr	ccc Pro	gac Asp	atg Met	gag Glu	agc Ser	462	
gac Asp -40	acc Thr	gtg Val	gtg Val	gtc Val	gag Glu	gtg Val	ctg Leu	gag Glu	ggc Gly	tcc Ser	gac Asp -30	gcc Ala	gac Asp	gtc Val	gcc Ala	510	
gcc Ala -25	ctg Leu	ctc Leu	gcc Ala	gac Asp	ggc Ala	gtg Gly	gtg Val	gac Asp	gcc Ala	tcc Ser -15	gcc Ala	gtc Val	cgg Arg	gtg Val	gag Glu -10	558	
gag Glu	gag Ala	gag Glu	gag Glu	gtc Val -5	ccg Pro	cag Gln	gtc Val	tac Tyr -1	gcc Ala 1	aac Asn	atc Ile	atc Ile	ggc Gly 5	ggc Gly	ctg Leu	606	
gcc Ala	tac Tyr	acc Thr 10	atg Met	ggc Gly	gga Gly	cgc Arg	tgc Cys 15	tcc Ser	gtc Val	ggc Gly	ttc Phe 20	gag Ala	gag Ala	acc Thr	aac Asn	654	
agc Ser 25	gcc Ala	gga Gly	cag Gln	ccc Pro	ggt Gly	ttc Phe 30	gtg Val	acg Thr	gag Ala	ggc Gly	cac His 35	tgc Cys	ggc Gly	acc Thr	gtc Val	702	
ggc Gly 40	acc Thr	gcc Ala	gtg Val	acc Thr	atc Ile 45	ggc Gly	gac Asp	ggc Gly	cgc Arg	ggc Gly 50	gtc Val	ttc Phe	gag Glu	cgc Arg	tcc Ser 55	750	
gtc Val	ttc Phe	ccc Pro	ggc Gly	aac Asn 60	gac Asp	gcc Ala	gcc Ala	ttc Phe 65	gtc Val	cgc Arg	ggc Gly	acc Thr	tcc Ser	aac Asn 70	ttc Phe	798	
acc Thr	ctg Leu	acc Thr 75	aac Asn	ctg Leu	gtc Val	tcc Ser	cgc Arg	tac Tyr 80	aac Asn	tcc Ser	ggc Gly	ggc Gly	cac His 85	cag Gln	gag Ala	846	
gtg Val	acc Thr 90	ggc Gly	acc Thr	agc Ser	cag Gln	gcc Ala	ccg Pro 95	gcc Ala	ggc Gly	tcc Ser	gcc Ala	gtc Val	tgc Cys	cgc Arg	tcc Ser	894	
ggc Gly 105	tcc Ser	acc Thr	acc Thr	ggc Gly	tgg Trp	cac His 110	tgc Cys	ggc Gly	acc Thr	atc Ile	cag Gln 115	gcc Ala	cgc Arg	aac Asn	cag Gln	942	
acc Thr 120	gtg Val	cgc Arg	tac Tyr	ccg Pro	cag Gln 125	ggc Gly	acc Thr	gtc Val	aac Asn	gag Ala 130	ctc Leu	acc Thr	cgc Arg	acc Thr	aac Asn 135	990	
gtg Val	tgc Cys	gcc Ala	gag Glu	ccc Pro	ggt Gly	gac Asp	tcc Ser	ggc Gly	ggc Gly	tcc Ser	ttc Phe	atc Ile	tcc Ser	ggc Gly	tcc Ser	1038	

10436.504-WO.ST25

140	145	150	
cag gcc cag ggc gtc acc tcc ggc ggc tcc ggc aac tgc tcc ttc ggc			1086
Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Phe Gly			
155	160	165	
ggc acg acc tac tac cag gag gtc gcc ccg atg atc aac tcc tgg ggc			1134
Gly Thr Thr Tyr Tyr Gln Glu Val Ala Pro Met Ile Asn Ser Trp Gly			
170	175	180	
gtt cgc atc cgc acc agc tga			1155
Val Arg Ile Arg Thr Ser			
185			

<210> 10  
 <211> 384  
 <212> PRT  
 <213> Nocardiosis sp. DSM 16424  
 <400> 10

Met Arg Pro Ser Thr Ile Ala Ser Ala Val Gly Thr Gly Ala Leu  
 -195 -190 -185

Ala Phe Gly Leu Ala Leu Ser Met Ala Pro Gly Ala Leu Ala Ala  
 -180 -175 -170

Pro Gly Pro Val Pro Gln Thr Pro Val Ala Asp Asp Ser Ala Ala  
 -165 -160 -155

Ser Met Thr Glu Ala Leu Lys Arg Asp Leu Asn Leu Ser Ser Ala  
 -150 -145 -140

Glu Ala Glu Glu Leu Leu Ser Ala Gln Glu Ala Ala Ile Glu Thr  
 -135 -130 -125

Asp Ala Glu Ala Ala Glu Ala Ala Gly Glu Ala Tyr Gly Gly Ser  
 -120 -115 -110

Leu Phe Asp Thr Glu Thr Leu Glu Leu Thr Val Leu Val Thr Asp Thr  
 -105 -100 -95 -90

Thr Ala Val Asp Ala Val Glu Ala Thr Gly Ala Glu Ala Thr Val Val  
 -85 -80 -75

Thr His Gly Thr Asp Gly Leu Ala Glu Val Val Glu Asp Leu Asn Ser  
 -70 -65 -60

Ala Asp Ala Pro Ala Gly Val Leu Gly Trp Tyr Pro Asp Met Glu Ser  
 -55 -50 -45

Asp Thr Val Val Val Glu Val Leu Glu Gly Ser Asp Ala Asp Val Ala  
 -40 -35 -30

Ala Leu Leu Ala Asp Ala Gly Val Asp Ala Ser Ala Val Arg Val Glu  
 -25 -20 -15 -10

10436.504-WO.ST25

Glu Ala Glu Glu Val Pro Gln Val Tyr Ala Asn Ile Ile Gly Gly Leu  
                     -5                    -1 1                    5  
 Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala Thr Asn  
           10                    15                    20  
 Ser Ala Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly Thr Val  
       25                    30                    35  
 Gly Thr Ala Val Thr Ile Gly Asp Gly Arg Gly Val Phe Glu Arg Ser  
   40                    45                    50                    55  
 Val Phe Pro Gly Asn Asp Ala Ala Phe Val Arg Gly Thr Ser Asn Phe  
                     60                    65                    70  
 Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Ser Gly Gly His Gln Ala  
                     75                    80                    85  
 Val Thr Gly Thr Ser Gln Ala Pro Ala Gly Ser Ala Val Cys Arg Ser  
           90                    95                    100  
 Gly Ser Thr Thr Gly Trp His Cys Gly Thr Ile Gln Ala Arg Asn Gln  
      105                    110                    115  
 Thr Val Arg Tyr Pro Gln Gly Thr Val Asn Ala Leu Thr Arg Thr Asn  
   120                    125                    130                    135  
 Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser Gly Ser  
          140                    145                    150  
 Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser Phe Gly  
          155                    160                    165  
 Gly Thr Thr Tyr Tyr Gln Glu Val Ala Pro Met Ile Asn Ser Trp Gly  
      170                    175                    180  
 Val Arg Ile Arg Thr Ser  
      185

<210> 11  
 <211> 1068  
 <212> DNA  
 <213> Nocardiosis alba DSM 15647

<220>  
 <221> CDS  
 <222> (1)..(1065)  
 <220>  
 <221> mat\_peptide  
 <222> (502)..(1065)

10436.504-WO.ST25

&lt;220&gt;

&lt;221&gt; sig\_peptide

&lt;222&gt; (502)..(1065)

&lt;400&gt; 11

gcg acc ggc	ccc ctc ccc cag tcc	ccc acc ccg gat gaa	gcc gag	45
Ala Thr Gly	Pro Leu Pro Gln Ser	Pro Thr Pro Asp Glu	Ala Glu	
-165	-160	-155		
gcc acc acc	atg gtc gag gcc ctc	cag cgc gac ctc ggc	ctg tcc	90
Ala Thr Thr	Met Val Glu Ala Leu	Gln Arg Asp Leu Gly	Leu Ser	
-150	-145	-140		
ccc tct cag	gcc gac gag ctc ctc	gag gcg cag gcc gag	tcc ttc	135
Pro Ser Gln	Ala Asp Glu Leu Leu	Glu Ala Gln Ala Glu	Ser Phe	
-135	-130	-125		
gag atc gac	gag gcc gcc acc gcg	gcc gca gcc gac tcc	tac ggc	180
Glu Ile Asp	Glu Ala Ala Thr Ala	Ala Ala Ala Asp Ser	Tyr Gly	
-120	-115	-110		
ggc tcc atc	ttc gac acc gac agc	ctc acc ctg acc gtc	ctg gtc acc	228
Gly Ser Ile	Phe Asp Thr Asp Ser	Leu Thr Leu Thr Val	Leu Val Thr	
-105	-100	-95		
gac gcc tcc	gcc gtc gag gcg gtc	gag gcc gcc ggc gcc	gag gcc aag	276
Asp Ala Ser	Ala Val Glu Ala Val	Glu Ala Ala Gly Ala	Glu Ala Lys	
-90	-85	-80		
gtg gtc tcg	cac ggc atg gag ggc	ctg gag gag atc gtc	gcc gac ctg	324
Val Val Ser	His Gly Met Glu Gly	Leu Glu Glu Ile Val	Ala Asp Leu	
-75	-70	-65		
aac gcg gcc	gac gct cag ccc ggc	gtc gtg ggc tgg tac	ccc gac atc	372
Asn Ala Ala	Asp Ala Gln Pro Gly	Val Val Gly Trp Tyr	Pro Asp Ile	
-55	-50	-45		
cac tcc gac	acg gtc gtc ctc	gag gtc ctc	gag ggc tcc	420
His Ser Asp	Thr Val Val Leu	Glu Val Leu	Glu Gly Ser	
-40	-35	-30		
gtg gac tcc	ctg ctc gcc gac	gcc ggt gtg gac	acc gcc gac	468
Val Asp Ser	Leu Leu Ala Asp	Ala Gly Val Asp	Thr Ala Asp	
-25	-20	-15		
gtg gag agc	acc acc gag cag ccc	gag ctg tac gcc	gac atc atc	516
Val Glu Ser	Thr Thr Glu Gln	Pro Glu Leu Tyr	Ala Asp Ile	
-10	-5	-1	1	5
ggt ctc gcc	tac acc atg ggt	ggg cgc tgc	tcg gtc ggc	564
Gly Leu Ala	Tyr Thr Met Gly	Gly Arg Cys	Ser Val Gly	
10	15	20		
acc aac gcc	tcc ggc cag ccc	ggg ttc gtc	acc gcc ggc	612
Thr Asn Ala	Ser Gly Gln Pro	Gly Phe Val	Thr Ala Gly	
25	30	35		
acc gtc ggc	acc ccg gtc agc	atc ggc aac	ggc cag ggc	660
Thr Val Gly	Thr Pro Val Ser	Ile Gly Asn	Gly Gln Gly	
40	45	50		
cgt tcc gtc	ttc ccc ggc aac	gac tcc gcc	ttc gtc cgc	708
Arg Ser Val	Phe Pro Gly Asn	Asp Ser Ala	Phe Val Arg	
55	60	65		
aac ttc acc	ctg acc aac ctg	gtc agc cgc	tac aac acc	756
Asn Phe Thr	Leu Thr Asn Leu	Val Ser Arg	Tyr Asn Thr	
70	75	80		



## 10436.504-WO.ST25

gcg acc gtc tcc ggc tcc tcg cag gcg gcg atc ggc tcg cag atc tgc 804  
 Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys  
 90 95 100

cgt tcc ggc tcc acc acc ggc tgg cac tgc ggc acc gtc cag gcc cgc 852  
 Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg  
 105 110 115

ggc cag acg gtg agc tac ccc cag ggc acc gtg cag aac ctg acc cgc 900  
 Gly Gln Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg  
 120 125 130

acc aac gtc tgc gcc gag ccc ggt gac tcc ggc ggc tcc ttc atc tcc 948  
 Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser  
 135 140 145

ggc agc cag gcc cag ggc gtc acc tcc ggt ggc tcc ggc aac tgc tcc 996  
 Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser  
 150 155 160 165

ttc ggt ggc acc acc tac tac cag gag gtc aac ccg atg ctg agc agc 1044  
 Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser  
 170 175 180

tgg ggt ctg acc ctg cgc acc tga 1068  
 Trp Gly Leu Thr Leu Arg Thr  
 185

<210> 12  
 <211> 355  
 <212> PRT  
 <213> Nocardiosis alba DSM 15647

<400> 12

Ala Thr Gly Pro Leu Pro Gln Ser Pro Thr Pro Asp Glu Ala Glu  
 -165 -160 -155

Ala Thr Thr Met Val Glu Ala Leu Gln Arg Asp Leu Gly Leu Ser  
 -150 -145 -140

Pro Ser Gln Ala Asp Glu Leu Leu Glu Ala Gln Ala Glu Ser Phe  
 -135 -130 -125

Glu Ile Asp Glu Ala Ala Thr Ala Ala Ala Ala Asp Ser Tyr Gly  
 -120 -115 -110

Gly Ser Ile Phe Asp Thr Asp Ser Leu Thr Leu Thr Val Leu Val Thr  
 -105 -100 -95

Asp Ala Ser Ala Val Glu Ala Val Glu Ala Ala Gly Ala Glu Ala Lys  
 -90 -85 -80

Val Val Ser His Gly Met Glu Gly Leu Glu Glu Ile Val Ala Asp Leu  
 -75 -70 -65 -60

Asn Ala Ala Asp Ala Gln Pro Gly Val Val Gly Trp Tyr Pro Asp Ile  
 -55 -50 -45

10436.504-WO.ST25

His Ser Asp Thr Val Val Leu Glu Val Leu Glu Gly Ser Gly Ala Asp  
 -40 -35 -30  
 Val Asp Ser Leu Leu Ala Asp Ala Gly Val Asp Thr Ala Asp Val Lys  
 -25 -20 -15  
 Val Glu Ser Thr Thr Glu Gln Pro Glu Leu Tyr Ala Asp Ile Ile Gly  
 -10 -5 -1 1 5  
 Gly Leu Ala Tyr Thr Met Gly Gly Arg Cys Ser Val Gly Phe Ala Ala  
 10 15 20  
 Thr Asn Ala Ser Gly Gln Pro Gly Phe Val Thr Ala Gly His Cys Gly  
 25 30 35  
 Thr Val Gly Thr Pro Val Ser Ile Gly Asn Gly Gln Gly Val Phe Glu  
 40 45 50  
 Arg Ser Val Phe Pro Gly Asn Asp Ser Ala Phe Val Arg Gly Thr Ser  
 55 60 65  
 Asn Phe Thr Leu Thr Asn Leu Val Ser Arg Tyr Asn Thr Gly Gly Tyr  
 70 75 80 85  
 Ala Thr Val Ser Gly Ser Ser Gln Ala Ala Ile Gly Ser Gln Ile Cys  
 90 95 100  
 Arg Ser Gly Ser Thr Thr Gly Trp His Cys Gly Thr Val Gln Ala Arg  
 105 110 115  
 Gly Gln Thr Val Ser Tyr Pro Gln Gly Thr Val Gln Asn Leu Thr Arg  
 120 125 130  
 Thr Asn Val Cys Ala Glu Pro Gly Asp Ser Gly Gly Ser Phe Ile Ser  
 135 140 145  
 Gly Ser Gln Ala Gln Gly Val Thr Ser Gly Gly Ser Gly Asn Cys Ser  
 150 155 160 165  
 Phe Gly Gly Thr Thr Tyr Tyr Gln Glu Val Asn Pro Met Leu Ser Ser  
 170 175 180  
 Trp Gly Leu Thr Leu Arg Thr  
 185

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/DK2004/000432

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/58 C12N9/52 C12N15/57 A23J3/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, FSTA, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/58276 A (HOFFMANN LA ROCHE ; OESTERGAARD PETER RAHBEK (DK); SJOEHOLM CARSTEN (D) 16 August 2001 (2001-08-16) cited in the application the whole document	1-18
E	WO 2004/072221 A (DE MARIA LEONARDO ; NOVOZYMES AS (DK); OESTERGAARD PETER RAHBEK (DK)) 26 August 2004 (2004-08-26) the whole document	1-18
A	MITSUIKI SHINJI ET AL: "Purification and some properties of a keratinolytic enzyme from an alkaliphilic Nocardiosis sp. TOA-1" BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 66, no. 1, January 2002 (2002-01), pages 164-167, XP002296335 ISSN: 0916-8451	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

15 September 2004

Date of mailing of the international search report

01/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Piret, B

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/DK2004/000432

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0158276	A	16-08-2001	AU 3544601 A	20-08-2001
			AU 4236601 A	20-08-2001
			BR 0108164 A	21-01-2003
			BR 0108165 A	25-02-2003
			CA 2395266 A1	16-08-2001
			CA 2395343 A1	16-08-2001
			CN 1398161 T	19-02-2003
			CN 1398162 T	19-02-2003
			WO 0158275 A2	16-08-2001
			WO 0158276 A2	16-08-2001
			EP 1257175 A2	20-11-2002
			EP 1257176 A2	20-11-2002
			JP 2003521907 T	22-07-2003
			JP 2003521908 T	22-07-2003
			PL 357638 A1	26-07-2004
			PL 357668 A1	26-07-2004
			US 2004161448 A1	19-08-2004
			US 2001026797 A1	04-10-2001
			US 2003021774 A1	30-01-2003
WO 2004072221	A	26-08-2004	WO 2004072221 A2	26-08-2004
			WO 2004072279 A2	26-08-2004